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The ability of ligands to differentially regulate the activity of signaling pathways 
coupled to a receptor potentially enables researchers to optimize therapeutically relevant 
efficacies, while minimizing activity at pathways that lead to adverse effects. Recent studies 
have demonstrated the functional selectivity of kappa opioid receptor (KOR) ligands acting 
at KOR expressed by rat peripheral pain sensing neurons. In addition, KOR signaling leading 
to antinociception and dysphoria occur via different pathways. Based on this information, it 
can be hypothesized that a functionally selective KOR agonist would allow researchers to 
optimize signaling pathways leading to antinociception while simultaneously minimizing 
activity towards pathways that result in dysphoria. 
In this study, our goal was to alter the structure of U50,488 such that efficacy was 
maintained for signaling pathways important for antinociception (inhibition of cAMP 
accumulation) and minimized for signaling pathways that reduce antinociception. Thus, 
several compounds based on the U50,488 scaffold were designed, synthesized, and evaluated 
at KORs. Selected analogues were further evaluated for inhibition of cAMP accumulation, 
activation of extracellular signal-regulated kinase (ERK), and inhibition of calcitonin gene-
related peptide release (CGRP). 
The data obtained demonstrates that modification of the structure of U50,488 changed 
the signaling pathway regulation. Specifically, we identified three functionally selective 
KOR ligands (4b, 9u, and 9ac) that inhibit cAMP accumulation, similar to U50,488, but, 
unlike U50,488, do not activate ERK. In addition, the ability to inhibit CGRP release showed 
monotonic concentration-response curves, indicating that a pathway leading to nociception 
is not activated. These data suggest that the efficacy for specific signaling pathways can be 
finely tuned by structural modifications to a given ligand. 
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Historical Aspects of Opioids 
  
Opium, or poppy tears, refers to the dried latex produced by the opium poppy, 
Papaver somniferum.1 This particular strain is the evolution of centuries of cultivation and 
breeding that originated with a wild strain, Papaver setigerum.1 Today, Papaver somniferum 
is the only species used to produce opium.1 Carbon-14 dating indicates that the opium poppy 
has been used since as early as 4200 BC.1 The earliest findings of cultivation of opium dates 
back to 3400 BC in Mesopotamia.2-4 There, Sumerians referred to the poppy as Hul Gil, 
which translates to the “joy plant”.1-3,5 Eventually, use of the poppy to treat pain and other 
ailments spread to every major civilization in ancient Europe and Asia.2,5-8 
Western medicine continued to uncover the positive potential of opium.9 In spite of 
the addictive nature, there was no better substitute to opium, and its use prevailed.9 During 
the 19th century, the use of analgesics transitioned from opium to opioids with gradually 
stronger effects.2 Specifically, there are four main alkaloids in opium, as follows: morphine, 
codeine, thebaine, and papaverine5 (Figure 1.1). In 1803, Sir William Seturner isolated and 
identified the alkaloid morphine, named after Morpheus, the Greek god of dreams.2-4 Shortly 
following, Pierre Robiquet isolated codeine in 1832,10 Thiboumery and Pelletier identified 
thebaine in 1835,11 and Merck extracted papaverine in 1848.12 Successful isolations of these 
opiates paved the way for chemists who would improve upon these compounds.2 
Figure 1.1. Structures of the main alkaloids found in opium. 
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In 1874, C. R. Alder Wright synthesized the earliest opiate, diacetylmorphine, more 
commonly known as heroin (Figure 1.2).13 The hypothesis was 
that by acetylating morphine, they would produce a drug like 
codeine, which is pharmacologically similar to morphine, but less 
potent and less addictive.14 Bayer Pharmaceutical Company then 
started the production of heroin in 1898 on a commercial scale.14 
Bayer named the drug “heroin”, based on the German heroisch, which means “heroic”, and 
proclaimed that this new compound had less habit-forming potential than morphine.14 From 
1898 to 1920, the drug was erroneously marketed as a non-addictive substitute for 
morphine.14 By the 1920s, however, evidence of heroin’s risks prompted recall of the drug.13 
The failure of this “heroic” drug to cure morphine addiction instigated the search for non-
addictive opioids.2 
 
Identification of the Opioid Receptors 
 
Although morphine had been used as a potent analgesic since its isolation by Seturner, 
the idea of opioid receptor was not proposed until 1954 when Beckett and Casy suggested, 
based on their structure-activity relationships (SAR) for antinociceptive activity, that a 
specific receptor for opiate drugs must exist.15 In order to prove this theory, Goldstein et al.16 
suggested that radiolabeled drugs would demonstrate the existence of multiple receptors and 
allow for their characterization. Unfortunately, their efforts failed because they did not have 
radioligands with high specific activities.16 In 1973, however, Pert and Snyder,17 Simon et 
al.,18 and Terenius19 succeeded almost simultaneously in showing that there are stereospecific 
opiate binding sites in the central nervous system. Opioid receptors were found to have a 
nonuniform distribution, suggesting that these receptors might be the targets of endogenous 
peptides.3 Shortly thereafter, several endogenous peptides were discovered with high affinity 
Figure 1.2. Structure  
of heroin. 
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for brain opioid receptors: the enkephalins,20 β-endorphin,21 and dynorphin,22 as depicted in 
Figure 1. 3.  
By the mid-1960s, it was becoming apparent that opiate drugs were likely to exert 
their actions at specific receptor sites, and that there were likely to be multiple such sites.3 
The first conclusive evidence for multiple opioid receptors was provided in 1976 by Martin 
et al.22 Specifically, researchers analyzed the neurophysiological and behavioral properties 
of several opiate compounds and looked for “cross tolerance” (i.e. the ability of a drug to 
prevent withdrawal symptoms after removal of the second drug from an animal tolerant to 
it). The results of these experiments suggested the existence of three types of receptors. 
Specifically, the opioid receptor subtypes are as follows: the δ (delta) receptor, named after 
the mouse vas deferens tissue preparation (the prototypical agonist for this receptor is N-
allylnormetazocine);23 the µ (mu) receptor, named after its well-known agonist, morphine; 
and κ (kappa), named after 
ketocyclazocine, the agonist first used to 
characterize it.24-25 The structures of the 
prototypical agonists for the delta and 
kappa receptors are shown in Figure 1.4.  
The functional roles each of the receptor subtypes will be described herein. To begin, 
the delta opioid receptor (DOR) mediates the analgesic effects of delta agonists.26 It also plays 
a role in gastrointestinal motility, mood and behavior, as well as cardiovascular regulation.26 
Figure 1.3. Amino acid sequences of the endogenous opioid peptides. 
Figure 1.4. Structures of prototypical opioid 
ligands. 
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Of the three opioid receptor families, the mu opioid receptor (MOR) subtype is the most 
extensively studied.15-19 Morphine alkaloids and many of their synthetic derivatives are 
selective agonists at the MOR.26 The most commonly used narcotic agents include morphine, 
codeine, hydrocodone, oxycodone, and fentanyl,27 the structures of which are shown in 
Figure 1.5. These compounds are some of the most potent analgesics used in the clinic.27  
While they are a popular choice for the treatment of severe pain, unfortunately they have 
several dose-limiting side effects, including respiratory depression, constipation, tolerance, 
and dependence.28  Thus, when the kappa opioid receptor (KOR) subtype was first 
distinguished, there was tremendous interest in developing analgesics that would provide pain 
relief without activating the reward pathways stimulated by morphine-like mu opioids.29-44 A 
non-addictive opioid has been a holy grail of medicinal chemistry ever since morphine was 
first isolated from opium in 1804.27 Selective kappa agonists were developed and were shown 
to reduce the rewarding effect of co-administered addictive drugs and lack many of the dose-
limiting side effects of current opioid analgesics.28,44 However, these drugs were quickly 
found to produce different problems, including dysphoria, diuresis, and constipation.28  
Although pharmacological differences amongst the opioid receptor subtypes have 
been described since the early 1970s, the subtypes were not cloned and purified until the 
1990s. The first opioid receptor to be cloned was the DOR.45-46 This was accomplished 
simultaneously and independently by Keiffer et al.45 and Evans et al.46 Shortly after, the KOR 
Figure 1.5. Structures of the five most commonly prescribed narcotics. 
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was isolated and cloned by Meng et al.47 and the MOR was cloned by Wang et al.48 The data 
confirmed what scientists already believed, that opioid receptors are in fact members of the 
G protein-coupled receptor (GPCR) family.45-48 
 
G-Protein Coupled Receptors (GPCRs) 
 
All of the opioid ligands exert their effects via the opioid receptors, which are 
GPCRs.3 GPCRs are seven-transmembrane cell surface receptors which are responsible for 
regulating a variety of physiological events.49 Specifically, GPCRs are the largest and most 
diverse family of cell surface receptors.50 It is estimated that 50% of the currently marketed 
drugs directly target GPCRs or their downstream effectors.49 GPCRs share a common 
structure composed of seven hydrophobic transmembrane segments with an extracellular 
amino acid terminus and an intracellular carboxyl terminus (Figure 1.6).50 Although there is 
variation regarding the structure of GPCRs, there are two main requirements for 
classification. First of all, the 
protein must have seven 
sequence stretches of about 
25 to 35 consecutive 
residues that have a high degree of hydrophobicity.49 These sequences represent the seven α-
helices that span the plasma membrane in a counter-clockwise manner, which enable an 
extracellular ligand to exert a specific effect.49 Secondly, the receptor must be able to interact 
with a G-protein.49 The portions of a GPCR with the greatest variation are the carboxyl 
terminus, the intracellular loops, and the amino terminus.51 In contrast to the structural and 
functional similarity of GPCRs, GPCR ligands have tremendous variation, which include 
subatomic particles (photons), ions, small organic molecules, lipids, nucleotides, peptides, 
Figure 1.6. Depiction of a prototypical 7-transmembrane receptor. 
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and proteins.49  
Despite the variations in the receptors and ligands, the cellular signaling of GPCRs is 
largely conserved.52 A representative depiction of GPCR signaling is shown in Figure 1.7. 
Upon activation by a ligand, the 
GPCR will undergo a 
conformational change which 
activates an associated G protein 
by exchanging GDP for GTP.52 
This leads to dissociation of the 
αβγ-complex into the α subunit with the bound GTP and the βγ subunit.52 Both of these 
moieties then become free to act upon their downstream effectors and thereby initiate unique 
intracellular signaling responses.52 Thus, science has demonstrated that GPCRs are a large, 
versatile class of plasma membrane receptors.49-52 However, despite their central role in 
biomedical research, scientists are still gaining insight into the mechanistic details underlying 
receptor activation.52-54 
 
Receptor Pharmacology Towards the Theory of Functional Selectivity 
 
The concept of drug receptors began as an abstract idea, which then led to models that 
considered receptors as pharmacological switches, which laid the foundation for the more 
mechanistically driven models of receptors in use today.53-54 At the turn of the 20th century, 
different groups postulated the existence of control points on cells that responded to 
chemicals.55 Historically, scientists believed that GPCRs acted as molecular switches, which 
posited that GCPRs could exist in two different conformations: the inactive state, functionally 
and physically uncoupled from the G protein and the active state which was associated with 
a G protein, resulting in its activation (Figure 1.8).55-56 A.J. Clark, who is largely considered 
Figure 1.7. Depiction of GPCR signaling. 
β 𝛾 
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the father of modern 
receptor pharmacology, 
was the first to suggest 
that a unimolecular 
interaction occurs between a drug and a substance on the cell.57 Extending this theory, R. P. 
Stephenson postulated the existence of a theoretical parameter called “stimulus” when he 
observed different potencies for compounds that had similar receptor affinities.58 This 
concept of efficacy allowed for powerful agonists that could produce maximal tissue response 
by activating only a portion of the available receptors; the remaining portion being referred 
to as “spare”.58 However, upon discovering that an agonist is not necessarily required to 
toggle receptors, this theory was replaced by a more complex model that accounts for 
multiple conformations assumed by the receptor.59 This model, referred to as the two-state 
model of GPCR activation was developed in the mid-1990s.60 In this paradigm, GPCRs 
isomerize between an inactive (R) state and an active (R*) state, as shown in Figure 1.9.59 
The affinity of the agonist for each of the two states is governed by the dissociation 
equilibrium constants, 
KA and KA*.59 This 
contrasts with the 
aforementioned receptor theory which defines agonist affinity by a single constant.58 In 
addition, the efficacy of an agonist is dependent on KA and KA*, which allows for 
determination of the degree to which an agonist displaces receptors towards the active state.59 
This concept is referred to as “intrinsic efficacy” and can be described as a measure of the 
stimulus per receptor molecule produced by a ligand.61 This concept has led to the 
 
Figure 1.9. Representation of the two-state model of receptor activation. 
Figure 1.8. Representation of receptors as molecular switches. 
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classification of receptor ligands as full agonists, partial agonists, antagonists, or inverse 
agonists, as depicted in Figure 1.10.61 According to this notion, full agonists possess 
sufficiently high intrinsic efficacy, such that they maximally stimulate all 
cellular responses linked to a given 
receptor.61 Partial agonists possess 
lower degrees of intrinsic efficacy 
leading to submaximal responses.61 
Antagonists possess no intrinsic 
efficacy, but occupy the receptor 
to block the effects of agonists.61 This idea has also lead to the assumption in pharmacology 
that the ability of the ligand to impart stimulus once that ligand is bound to the receptor is an 
inherent property of the ligand-receptor complex.61 Therefore, a full agonist would be 
expected to activate all of the signaling pathways linked to a receptor to the same degree as 
the endogenous ligand for that receptor.61 
The notion that intrinsic efficacy is system-independent forms a major underlying 
premise in drug discovery today – that the pharmacological characteristics of a drug tested in 
an experimental model system can be extrapolated to all systems.61 In the past decade, 
however, data has emerged in which certain ligands were shown to have quite diverse 
functional consequences mediated via a single receptor.61 At first, these observations were 
simply dismissed as artifacts. However, as more data has been amassed, it is becoming clear 
that “intrinsic efficacy” as a system-independent constant, is probably not correct.61 Thus, in 
order to rationalize these observations, the concept of functional selectivity was introduced. 







































Functional selectivity, also known as biased agonism, is the ability of ligands to 
differentially regulate the activity of specific signaling pathways coupled to a receptor.62 As 
shown in Figure 1.11, two drugs (represented as A and B) bind to the same receptor, yet have 
different efficacies for various pathways (efficacy for a particular pathway represented by the 
size of the arrow). As depicted below, Drug A is more efficacious for PLA2 and ERK than 
for activation of PLC and B-arr. On the other hand, Drug B has greater efficacy for PLC and 
β-arr. and produces less activation of ERK and PLA2. Essentially, the hypothesis is that 
ligands induce unique, ligand-specific receptor conformations that result in differential 
activation of signal transduction pathways associated with a particular receptor.62 This 
differential activation may be expressed as differences in intrinsic activity at one signaling 
pathways versus another that are not due to differences in affinity at the mediating receptor.62  
Two of the earliest studies reporting biased signaling showed that the capacities of 
agonists bound to α-2 adrenergic (α2AR)63 and cannabinoid receptors64 preferentially couple 
to Gαs or Gαi, which leads to different efficacies for cyclic AMP (cAMP) production. 
Subsequently, studies showed that different pathways can be triggered following activation 
of a single α2AR subtype with the same type of ligand.65 In addition, research regarding the 
β2-adrenergic receptor (β2AR) showed that G proteins also play a role in functional 
selectivity, possibly by inducing specific conformations of GPCRs to which they are 
Figure 1.11. Diverse functional consequences of two different ligands mediated via a single 
receptor. Efficacy is represented by the size of the arrow. A. Drug A is more efficacious for 
PLA2 and ERK, than for PLC and β-Arr. B. Drug B acts at the same receptor, but has greater 
efficacy towards PLC and β-Arr, than for PLA2 and ERK. 
A B A. B. 
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coupled.66 These studies reiterated the significance of GPCRs, namely that they can be 
considered “modular” entities that are capable of responding to distinct ligands with specific 
signaling outcomes depending on their specific sets of partners.55,67-68 
Today, there is a plethora of observations of functional selectivity including, but not 
limited to the following: Angiotensin II type I A receptors,69-70 5-HT2 serotonin receptors,71-
76 mu opioid receptors,77-79 β2-adrenergic receptors,80-83 V2 vasopressin receptors 84-86 D2L and 
D1 dopamine receptors,87-98 and of particular interest, kappa opioid receptors (KORs).29,99,100  
In order to highlight the potential implications of functional selectivity in drug design, 
angiotensin II Type 1A (AT1) receptors will briefly be examined. Ligands that target AT1 
receptors are one of the most well understood classes of functionally selective ligands.69-70,101-
103 These receptors play a key role in cardiovascular and renal regulation of blood pressure, 
along with a spectrum of other conditions, including endothelial dysfunction and atheroma, 
cardiac hypertrophy, atrial fibrillation, nephropathy, insulin resistance, and cancer.70,102 
Clinically, these molecules are especially interesting due to their multi-functionality. Ligands 
that target AT1 receptors function via two main signaling pathways: (a) the canonical G 
protein-dependent activation and (b) the G protein-independent recruitment of β-arrestin-
scaffolded signaling complexes.102,104-105 The G-protein mediated pathways have been shown 
to be deleterious by leading to increased myocyte size, apoptosis, and heart failure.104-105 The 
G-protein independent pathways that involve recruitment of β-arrestin, however, have been 
shown to promote cardioprotective signaling in response to stress.69,104-111 Many of the 
angiotensin-receptor blockers (ARBs) approved to treat heart failure block both G-protein 
and β-arrestin signaling.69,101-103 Fortunately, in 2002, a synthetically generated biased ligand 
known as SII (Sar1, Ile4, Ile8) was shown to be functionally selective in that it recruits β-
arrestin without inducing any G protein activity.112-114 In vivo treatment confirms that SII is 
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able to selectively antagonize harmful cardiac signaling while simultaneous potentiating 
beneficial pathways.115-116 Thus, SII is currently considered the gold-standard β-arrestin-
biased AT1 analog.117 
Although the concept of functional selectivity has not been largely incorporated in the 
pharmaceutical industry, the implications are extensive.62 Functional selectivity potentially 
enables researchers to optimize therapeutically relevant efficacies, while minimizing activity 
at pathways that lead to adverse effects.  
 
Functional Selectivity of the Kappa Opioid Receptor 
 
The therapeutic promise of kappa agonists in the treatment of pain has recently 
revived by studies showing that KORs exist as dynamic, multi-conformational protein 
complexes that can be directed by specific ligands towards distinct signaling pathways.62 In 
2007, Chavkin et al.118 began experiments that would help them understand how c-Jun-N-
terminal kinase (JNK) activation by certain KOR ligands disrupts KOR signaling. They found 
that the long duration of action of certain KOR antagonists was not a result of KOR 
downregulation, but rather that these ligands were exerting their effects via activation of 
JNK.62,118 Based on this information, they proposed that low-efficacy ligands that bind to the 
KOR without activating JNK may be short-acting antagonists.62,118 In 2010, Chavkin et al.119 
published their results, which showed that the KOR demonstrates ligand-directed 
selectivity.62,119 Specifically, their study shows that the dysphoric effects require activation 
of G-protein receptor kinase, arrestin recruitment, and subsequent p38 mitogen activated 
protein kinase (MAPK) activation, whereas their analgesic effects do not.29,62,119 On the basis 
of this concept, an analgesic KOR agonist that does not activate MAPK would not produce 
the associated dysphoria.29,62,119,120 
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Ligand-specific receptor conformations suggest that small modifications of ligand 
structures can have profound effects on signaling profiles.121-122 For example, in regards to 
opioid agonists, small structural changes to the KOR agonist, salvinorin A, have resulted in 
differentially regulated signaling pathways for the ligands depicted in Figure 1.12.100,124-125 
First of all, in 2008, research in the Prisinzano lab showed that replacement of the 2-acetoxy 
group of herkinorin, a MOR agonist based on the salvinorin A scaffold, with benzamide 
(yielding herkamide) results in greater β-arrestin 2 recruitment.124 Following this discovery, 
in 2012, 12-epi-salvinorin A was shown to have reduced activity for G protein activation, 
while retaining full activity for β-arrestin 2 recruitment.125 In addition, Berg et al.100 
established in 2015 that the ethoxymethyl derivative of salvinorin A (EOM-salvinorin B) had 
similar efficacy to G protein activation, but did not activate JNK as salvinorin A did. 
Interestingly, EOM-salvinorin B activated ERK to an extent similar to that of U50,488.100 
Nonetheless, the mechanism by which EOM-salvinorin B activated ERK differed from that 
of U50,488.100  
In addition, other functionally selective KOR ligands have been described in 
literature, which are shown in Figure 1.13. First of all, in 2013, researchers discovered the 
biased agonism of 6’-Guaninonaltridole (6’-GNTI).126-127 6’-GNTI is a potent partial agonist 
at the KOR for the G protein activation pathway, yet is an antagonist for recruiting β-
arrestins.126-127 Secondly, a series of triazole and isoquinolinone analogues were identified 
Figure 1.12. Salvinorin A and its analogues which differentially regulate signaling pathways.100,124-125 
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which produced a pronounced variation in bias between G protein signaling and ERK1/2 
activation, i.e. these analogues are full agonists in G protein signaling and they are able to 
recruit β-arrestin2, although at a greatly diminished potency.128-130 Additionally, researchers 
have discovered that nalfurafine is a G protein biased ligand with bias towards ERK1/2 
activation.131-132 Unfortunately, nalfurafine lacks receptor selectivity and its binding affinity 
for KOR is only between 2 and 15-fold higher than for the mu opioid receptor (MOR). 131-132 
Accordingly, these results demonstrate that small structural changes may lead to a 
KOR agonist that does not activate ERK or JNK.100 As highlighted above, studies have shown 
that small structural changes to the KOR agonist, salvinorin A, have resulted in differentially 
regulated signaling pathways.100,124-125 In addition, research utilizing several different 
scaffolds have afforded functionally selective molecules. Consequently, additional KOR 
agonist scaffolds should be investigated in order to determine if structural changes result in 






Figure 1.13. KOR agonists which differentially regulate signaling pathways.126-132 
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U50,488 as a Probe to Identify Functionally Selective KOR Ligands 
U50,488 is a KOR agonist that is a member of the arylacetamide class of 
compounds.120 It was first discovered in 1982 by the Upjohn Company and was of particular 
interest because unlike MOR ligands, it does not cause respiratory depression or constipation, 
and does not activate reward pathways.120 Following the discovery of this molecule, many 
researchers focused their efforts on improving selectivity of this molecule for the KOR over 
the MOR and DOR, as well as improving potency.125, 133-170 Notably, these efforts included 
work by Glaxo,100, 121-122 SmithKline Beecham,135-139 Sankyo,140 Parke-Davis,141-143 DuPont 
Merck,144-145 and Hoechst Marion Roussel.146-147  Despite successful efforts in regards to the 
selectivity and potency of U50,488 analogues, the clinical testing of a majority of these 
molecules was discontinued due to dose limiting dysphoria.148 There are four generalizations 
that can be made regarding the SAR of the arylacetamide class. First, the trans configuration 
is necessary for KOR agonistic activity, and the S,S configuration results in the greatest 
activity.171-172 Secondly, there is an “eastern methylene group” effect, simply meaning that 
the methylene group adjacent to the carbonyl is necessary for KOR selectivity.171 Third, 
substitution of the cyclohexane ring in either position para to the nitrogens produced, in many 
cases, potent MOR agonists.171-172 Fourth, fusion of a benzene ring onto the cyclohexane ring 
produces an active KOR agonist.171 A figure summarizing these overall structure-activity 
relationships (SARs) for U50,488 are presented in Figure 1.14. 
 Figure 1.14. Summary of U50,488 analgesic SARs.  
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In order to better understand the regulation of KORs, Berg et al.99 used (-)-U50,488 
in primary cultures of sensory neurons in a rat model of thermal allodynia. The data indicated 
that pretreatment with bradykinin (BK), which is an inflammatory mediator, was necessary 
for (-)-U50,488 to inhibit thermal allodynia. 
Contrarily, BK pretreatment was not required for, 
nor modified, the stimulation of the extracellular 
signal-regulated kinases (ERK) pathway by               
(-)-U50,488.99 This suggests that the adenylyl 
cyclase pathway, and not the ERK pathway, plays 
a role in mediating the anti-allodynic effect of      
(-)-U50,488.99 In addition, Berg et al.99 noted 
that the duration of the antiallodynic effect of (-)-U50,488 was inversely related to its dose, 
as shown in Figure 1.15. This suggests that in addition to the allodynic effects, this KOR 
ligand may initiate competing pronociceptive mechanisms.99 These results prompted further 
investigation regarding the inverted U-shaped dose response curve of (-)-U50,488.  
In order to study the regulation of KOR signaling in peripheral sensory neurons, 
cellular cAMP accumulation, ERK phosphorylation, and JNK were measured for the KOR 
selective agonists (-)-U50,488 and salvinorin A.100 In addition, opioid agonist-mediated 
changes in paw withdrawal latency (PWL) to a 
thermal stimulus were measured with a plantar 
test apparatus.100 The in vitro results show that       
(-)-U50,488 and salvinorin A inhibit PGE2-
stimulated adenylyl cyclase activity with similar 
efficacies, as shown in Figure 1.16.100 Despite 
Figure 1.15. Dose response curves for                        
(-)-U50,488 inhibition of PGE2-induced thermal 
allodynia in the rat hindpaw.99 
Figure 1.16. Inhibition of PGE2-stimulated cAMP 
accumulation by (-)-U50,488 and salvinorin A.100 
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the similarity in cAMP inhibition, (-)-U50,488 and salvinorin A differ in their ability to 
regulate ERK and JNK. As shown in Figure 1.17 (A), (-)-U50,488, but not salvinorin A, 
activated ERK in a nor-BNI sensitive manner (measured as a production of pERK). On the 
contrary, as depicted in Figure 1.17 (B), salvinorin A, but not (-)-U50,488 activated JNK, as 
measured by Western Blot.100  
In regards to the in vivo data, the PWL upon co-administration of nor-BNI and varying 
doses of (-)-U50,488 produced a rightward shift of the dose-response curve, indicating that 
both phases of the curve are mediated via the KOR.100 The roles of ERK and JNK on the 
descending phase of the dose-response curve for (-)-U50,488 were further examined.100 
Specifically, to study the role of ERK, the selective mitogen-activated protein kinase kinase 
½ inhibitor, U0126, was injected into the rat hindpaw 15 minutes before i.pl. injection of a 
dose of (-)-U50,488 or salvinorin A, respectively.100 Similarly, to study the role of JNK, the 
selective JNK inhibitor, SP600125, was injected prior to a dose of (-)-U50,488 or salvinorin 
A.100 As depicted in Figure 1.18 (A), the response to (-)-U50,488 was significantly enhanced 
by U0126, while SP600125 showed no effect.100 Conversely, as depicted in Figure 1.18 (B), 
the response to salvinorin A was enhanced by SP600125, while U0126 showed no effect.100 
These results show that the downward phase of the dose-response curves (DRCs) for                  
Figure 1.17. Activation of ERK (A) and JNK (B) by (-)-U50,488 and salvinorin A in primary 
cultures of peripheral sensory neurons.100 
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(-)-U50,488 and salvinorin A are differentially sensitive to kinase inhibitors.100 The 
differential, ligand-dependent signaling of KOR agonists to ERK and JNK, elicited by             
(-)-U50,488 and salvinorin A, respectively, provides evidence of the functional selectivity of 
KOR ligands in peripheral sensory neurons. 
 
In summary, recent studies have demonstrated the functional selectivity of KOR 
ligands in rat peripheral pain sensing neurons.99,100 In addition, researchers have 
demonstrated that receptor signaling leading to antinociception and dysphoria occur via 
different pathways.29,62,119 Currently, there is a wealth of research and literature data in 
regards to the arylacetamide class of compounds.120-172 Despite this abundance of knowledge, 
to-date, no medicinal chemistry campaign has been launched in order to identify functionally 
selective ligands based on the U50,488 scaffold. Consequently, there exists a gap in the 
knowledge regarding the potential of known arylacetamides to be functionally selective KOR 
agonists. Based on the information provided above, it can be hypothesized that a functionally 
selective KOR agonist, based on the U50,488 scaffold, would allow researchers to optimize 
signaling pathways leading to antinociception while simultaneously minimizing activity 
towards pathways that result in dysphoria. If successful, this has the potential to lead to new 
drugs with improved therapeutic profiles for the treatment of pain. 
 
Figure 1.18. The descending limb of the dose-response curve for (-)-U50,488 and 
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II. Rationale and Specific Aims 
Ligand efficacy for specific signaling pathways can be finely tuned by structural 
modifications of a ligand.1-2 In addition, the KOR demonstrates ligand-directed selectivity.3 
Specifically, researchers have shown that the dysphoric effects require activation of G-protein 
receptor kinase, arrestin recruitment, and subsequent p38 mitogen 
activated protein kinase (MAPK) activation, whereas their analgesic 
effects do not.3 On the basis of this concept, an analgesic KOR agonist that 
does not activate MAPK would not produce the associated dysphoria.3 Our 
central hypothesis is that the structure of U50,488 can be refined to 
produce ligands with high efficacy for inhibition of cAMP accumulation 
and low efficacy for ERK and JNK signaling.  
Specifically, we chose to use U50,488 as a scaffold, rather than salvinorin A due to 
the straightforward synthesis and cost effectiveness of U50,488 analogues. To begin, many 
analogues of U50,488 have been previously described in the literature dating back to the 
discovery of the arylacetamide class of KOR agonists.4-18 However, these were investigated 
before studies demonstrating that KORs exist as dynamic, multi-conformational protein 
complexes that can be directed by specific ligands towards distinct signaling pathways.19 
Thus, there is a wealth of knowledge regarding the synthesis of U50,488 analogues that can 
be utilized in order to study the effects of structural changes on signaling pathways. In 
addition, as depicted previously by the structure of salvinorin A (Figure 1.12) it is evident 
that salvinorin A is a much more complex molecule with seven chiral centers, whereas 
U50,488 has only two (Figure 2.1). Thus, the chemistry utilized in order to modify salvinorin 
A must involve mild reaction conditions, so as to avoid degradation of the molecule in other 
areas.  
Figure 2.1. Structure 
of U50,488. 
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In regards to the cost associated with the synthesis, it is much less expensive to 
generate analogues of U50,488. For example, purchasing 100 mg of salvinorin A or                   
(-)-U50,488 from Sigma Aldrich costs $1,500 and $930, respectively.20 In comparison, the 
prices for the stoichiometric reagents necessary for synthesis of U50,488 are as follows: 
cyclohexene oxide ($56.50 for 500mL), pyrrolidine ($82.10 for 500mL), methanesulfonyl 
chloride ($31.20 for 100mL), aqueous methylamine solution ($51.80 for 1 L), and 3,4-
dichlorophenylacetic acid ($63.20 for 25g).20 Thus, in regards to costs, it is evident that it is 
relatively inexpensive to synthesize large quantities of U50,488 analogues, using cheap, 
commercially available starting materials. In order to test our central hypothesis, we proposed 
the following: 
Specific Aim 1: Design and synthesize analogues of U50,488 and evaluate, in vitro, how 
modifications affect KOR activity. In order to better understand the relationship between 
structure and functional selectivity for U50,488 analogues, several sites were modified, as 
follows: the pyrrolidine group, the N-alkyl substituent, the linker region, the aryl group, and 
the cyclohexane ring. Although modifications to these regions have been explored in regards 
to analogues with increased affinity and potency, the effects on functional selectivity had not 
been investigated. In addition, we hypothesized that changes to more than one portion of the 
molecule would result in additive KOR activity. In order to test this hypothesis, we prepared 
analogues incorporating changes to two of the sites listed above. From the SAR trends 
elucidated for these analogues, we then identified compounds for further investigation. Our 
hypothesis is that ligands with activity inconsistent with our SAR trends may be promoting 
a unique receptor conformation with the ability to differentially regulate signaling pathways. 
Lastly, we prepared enantiopure ligands for the analogues which produced monotonic CRCs, 
as identified by specific aim #3. 
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Specific Aim #2: Evaluate ex vivo efficacy, including inhibition of cAMP accumulation 
and stimulation of ERK. Selected analogues identified in specific aim #1 then proceeded to 
ex vivo measurements of their efficacy to activate Gαi and ERK. For each ligand, full 
concentration response curves (CRCs) measuring inhibition of PGE2-stimulated cAMP 
accumulation and stimulation of ERK was completed. The analogues with signaling profiles 
with maintained or enhanced efficacy at Gαi signaling and reduced efficacy at ERK signaling 
were then tested for their efficacy to inhibit the release of calcitonin gene-regulated peptide 
(CGRP). 
Specific Aim #3: Evaluate ex vivo inhibition of CGRP release. Analogues with efficacy 
similar to (-)-U50,488, for signaling pathways leading to antinociception, and reduced 
efficacy for signaling pathways leading to nociception, were then assessed for their ability to 
inhibit calcitonin gene-regulated peptide (CGRP). CGRP is a neuropeptide released by the 
nerve endings of activated nociceptors and its neurosecretion can be used as an index of the 
overall, integrated activity of nociceptor ability.13 As such, this assay provides a translational 
measure for antinociception, i.e. the action of drugs to alter CGRP has high fidelity with their 
effects in the behavioral assay.  
Thus, by accomplishing the aims outlined above, we intend to show that structural 
modifications to the U50,488 scaffold will alter ligand efficacy for specific signaling 
pathways. We anticipate that these molecules will be useful biological probes for studying 
KOR-mediated antinociception. Ultimately, our long-term goal is that these ligands may lead 
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III. Results and Discussion 
In order to investigate the functional selectivity of KOR agonists, several compounds 
based on the U50,488 scaffold were synthesized and evaluated. Selected analogues were 
further evaluated for inhibition of PGE2-stimulated cAMP accumulation and activation of 
ERK in CHO cells transiently transfected with rat KORs. In addition, the ligands were 
assessed for their ability to inhibit calcitonin gene-related peptide (CGRP) release, as a 
translational measure for antinociception.  
 
Specific Aim 1: Design and synthesize analogues of U50,488 and evaluate, in vitro, how 
modifications affect KOR activity. To provide a more thorough representation of the how 
structural modification of U50,488 affects activity at the KOR, several analogues were 
designed.  
First of all, in regards to modification of the pyrrolidine group, several analogues were 
proposed (Figure 3.1). In order to evaluate steric effects, we aimed to increase the size of the 
pyrrolidine ring by one and two methylene units (4a-4b). The rationale is that by increasing 
the size of the pyrrolidine ring, we will identify if the 
pyrrolidine binds in a tight pocket in the receptor or if 
increasing lipophilicity increases KOR activity. Next, 
in order to gain information regarding how 
introduction of a second heteroatom affects KOR 
activity, we planned to substitute the pyrrolidine with 
morpholine and N-methylpiperazine, respectively (4c-4d). We envisioned that if an H-bond 
donor were present in the active site, then the morpholine analogue would have increased 
activity. Also, we chose a N-methyl piperazine substituent to determine how introduction of 
Figure 3.1. Proposed analogues with 
modifications of the pyrrolidine group. 
46  
a second heteroatom, which does not have H-bonding potential, affects KOR activity. To 
further probe the steric effects of this region, we proposed non-cyclic derivatives with varying 
degrees of alkylation (4e-4g). Specifically, we chose diethylamine and methypropylamine to 
mimic the size of the pyrrolidine group, in order to investigate the effects of conformational 
flexibility of this region. In addition, we also chose to substitute N-methylphenylethanamine 
in order to determine, as mentioned above, if the receptor binding region for this portion of 
the molecule tolerates larger substituents. We hypothesize that if the binding region is a small, 
specific, pocket, then the N-methylphenylethanamine analogue will eliminate KOR activity.  
Secondly, in regards to modification of the N-alkyl 
substituent, we designed two analogues (Figure 3.2). Specifically, we 
evaluated homologation to an ethyl and benzyl group (7a-7b). First, 
we chose homologation to an ethyl group to determine if the smallest 
change in the steric hindrance at this position is tolerated. We also 
decided to investigate the effect on KOR activity for substitution 
to a benzyl group to assess not only if larger substitutions were 
tolerated, but also if the addition of an aromatic ring would increase KOR activity. We 
hypothesized that if an aromatic amino acid was near the binding pocket for this particular 
substituent, then the addition of a benzyl group may allow favorable pi-stacking interactions, 
resulting in increased KOR activity. 
Third, we envisioned several analogues with modifications to the 3,4-dichlorophenyl 
ring (Figure 3.3). Based on previous SAR studies, we knew that 3,4-dichlorosubstitutents 
result in potent KOR activity.3-7 However, a systematic analysis of the effects of KOR activity 
on analogues with a single substituent or a change in substitution patterns has not been 
investigated. Thus, we proposed to examine the steric and electronic effects associated with 
Figure 3.2. Proposed 
analogues with modifications 
of the N-alkyl group. 
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various substitutions (9a-9q). The 
electronic differences in the substitutions 
spanned from strongly electron 
withdrawing groups, such as the nitro 
moiety (9j-9k), to electron donating 
groups, such as the methoxy moiety (9p-
9q). In addition, previous studies have 
shown that a benzo[b]thiophene and 
benzo[b]furan are potent KOR agonists.8 Therefore, we planned to synthesize analogues with 
a 4-Phenyl, 2-Napthyl, and 3-Napthyl group (9r-9t) to see if these analogues were also 
tolerated, or if the heteroatom in the analogues described above is interacting with the 
receptor to increase activity. To conclude our substitutions to the aryl group, we decided to 
investigate changes in substitution patterns for the halogens (9u-9y) to determine if alternate 
patterns are tolerated. As mentioned above, effects of changing the substitution patterns of 
U50,488 have not been thoroughly investigated. Therefore, we proposed to evaluate whether 
various dichloro- patterns were tolerated, whether a difluoro- analogue resulted in equivalent 
potency, and the effects of substituting a fluoro- for one of the chloro- groups. We 
hypothesize that the 2,4-substitution pattern, and replacement of the chloro- groups with 
fluoro- will not significantly change the KOR activity.  
Next, we proposed to investigate the role of the linker between the amide and aryl 
group (Figure 3.4). Specifically, we designed analogues in which the linker region was 
extended by one or two methylene units (9aa-9ab). We hypothesized that if the binding 
pocket for the aryl group is a deep pocket, then by extending the linker region, we may be 
able to gain more favorable interactions. However, if the binding pocket is a relatively tight 
Figure 3.3. Proposed analogues with modified aryl 
groups. 
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fit for the aryl group, then extension of the linker region will 
not be tolerated. In addition, in order to assess how the 
addition of a heteroatom affects the KOR activity, we 
designed an analogue incorporating an oxygen in the linker 
region (9ac). The rationale is that if the oxygen is in the 
proximity of a H-bond donor in the receptor pocket, then we 
will observe increased KOR activity as a result. Then, to 
evaluate the effects of conformational constraint of U50,488, we proposed analogues 
incorporating a cyclopropane and cyclopentane group (9ad-9ae), respectively. Thus, if we 
are able to lock the conformation of the molecule in its preferred position, we expect 
increased KOR activity. However, if conformational flexibility is preferred, we expect a loss 
of KOR activity. 
Finally, we planned to evaluate how KOR activity is 
affected by replacement of the cyclohexane ring (Figure 3.5). 
To begin, we designed an analogue where the cyclohexane 
core was replaced with an aromatic ring to assess the effects 
of a planar backbone which alters the basicity of the amine 
(12). A majority of KOR agonists require a basic nitrogen 
for their activity. However, certain analogues, such as salvinorin A, do not. Therefore, we 
proposed to synthesize this compound to determine if decreasing the basicity of the amine 
alters the KOR activity. In addition, the cyclohexane group was replaced with an ethylene 
linker to assess the effects of conformational flexibility of the molecule (14). Much like 
conformational constraint via a cyclopropyl or cyclopentyl group, we anticipated that if 
conformational flexibility of U50,488 was preferred, we would see an increase in KOR 
Figure 3.4. Proposed analogues 
with modifications to the linker 
region. 
Figure 3.5. Proposed analogues with 
modifications to the cyclohexane ring. 
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activity with cleavage of the cyclohexane ring; whereas, if the cyclohexane ring is locking 
the molecule in the preferred conformation, then cleavage would result in a loss of KOR. 
Finally, previous studies9 have shown that a non-fused phenyl ring results in potent KOR 
activity. Therefore, we synthesized this analogue adjacent to the amide in order to test the 
steric requirements for this particular position, as well as the preferred absolute configuration 
for this group (16a-16c). 
Synthesis of Proposed U50,488 Analogue 






The first step of the synthesis involves the reaction of cyclohexene oxide (1) and the 
amine (piperidine, morpholine, N-methyl piperazine, azepane, diethylamine, 
methylpropylamine, or N-methyl-2-phenylethanamine) at reflux, overnight (Scheme 3.1). 
This yields a 2-substituted cyclohexanol (2a-2g) in quantitative yields with no additional 























Scheme 3.1. Synthesis of U50,488 analogues with substituted pyrrolidine group. Reagents and 
conditions: a) R1, EtOH, 80oC, Overnight; b) MsCl, Et3N, 0oC, 2 hours; MeNH2, RT, Overnight; 
c) 3,4-dichlorophenylacetic acid, HOBt, DIPEA, EDCI, RT, 4 hours. 
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(MsCl) in the presence of triethylamine (Et3N). Addition of methylamine then generates a 
racemic mixture of the corresponding diamine (3a-3q). Finally, treatment of the appropriate 
diamine (3a-3q) with 3,4-dichlorophenylacetic acid, utilizing HOBt, DIPEA, and EDCI in 
DMF, at room temperature, gives the desired aryl acetamides (4a-4g). 
  
Homologation of the N-Alkyl Group of U50,488 
 Compounds 7a and 7b were 
prepared as shown in (Scheme 3.2). To 
begin, the aminocyclohexanol (5)1 was 
reacted with MsCl in the presence of Et3N, 
followed by ethylamine and 
benzylamine, respectively, to form the 
racemic diamine intermediate (6a-6b). 
Treatment of (6a-6b) with 3,4-
dichlorophenylacetic acid, utilizing 
Et3N and the catalyst, PyBrop, at 0oC to 
deliver the desired products (7a-7b).  
 
Analogues with Modification to the Aromatic Group and Linker Region 
The next series of analogues involved substitutions of the aryl group and modification 
of the linker region (Scheme 3.3). The racemic diamine (8)1 was reacted with various acids 
and acid chlorides utilizing three coupling methods to afford 9a-9ae. The first coupling 
method involved the treatment of 8 with the appropriate acid, utilizing HOBt, DIPEA, and 








Scheme 3.2. Synthesis of U50,488 analogues with 
modified N-alkyl substituents. Reagents and conditions: 
a) MsCl, Et3N, 0oC, 2 hours; R2NH2, RT, Overnight; b) 
3,4-dichlorophenylacetic acid, Et3N, PyBrop, 0oC, 1 hour. 
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acid chloride at 0oC. The third method, catalyzes the reaction between the appropriate acid 












b: 3-Cl A 
c: 4-Cl B 
 
d: 3-F A 






h: 3-CF3 C 
i: 4-CF3 C 
 
 
j: 3-NO2 A 
k: 4-NO2 A 
 
l: 2-CH3 A 
m: 3-CH3 A 




p: 3-OCH3 B 





























Scheme 3.3. Synthesis of U50,488 analogues with modified aryl groups (a-y) and modified linker regions 
(aa-ae). Reagents and conditions: a) Pyrrolidine, EtOH, 80oC, Overnight; b) MsCl, Et3N, 0oC, 2 hours; 
MeNH2, RT, Overnight; c) Method A: R3COOH, HOBt, DIPEA, EDCI, RT, Method B: R3COCl 0oC, 
Method C: R3COOH, Et3N, PyBrop, 0oC. 
AAnalogues prepared by Method A. 
BAnalogues prepared by Method B. 
CAnalogues prepared by Method C. 
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Analogues with Modification to the Cyclohexane Ring 
Synthesis of the first analogue, with the cyclohexane core as an aromatic ring began 
with commercially available 2-(pyrrolidine-1-yl)aniline (10), which was reacted with 3,4-
dichlorophenylacetic acid utilizing 
HOBt, DIPEA, and EDCI in DMF at 
room temperature (Scheme 3.4). This 
resulted in the intermediate (11), which 
was used to prepare the final 
compound (12) via the action of NaH 
and MeI. 
 
The cyclohexane ring was then replaced with an ethylene 
group (Scheme 3.5). Synthesis began from N-methyl-2-
(pyrrolidine-1-yl)ethan-1-amine (13). Upon condensation with 3,4-
dichlorophenylacetic acid utilizing HOBt, DIPEA, and EDCI in 
DMF at room temperature, the aryl acetamide (14) was formed. 
 
Lastly, an analogue with a 1-phenethyl core was 
synthesized (Scheme 3.6). Synthesis initiated from either 
the racemic starting material (15a), or the two enantiopure 
molecules (15b-15c), respectively, of N-Methyl-1-phenyl-
2-(1-pyrrolidinyl)ethylamine.  Reaction with 3,4-
dichlorophenylacetic acid with HOBt, DIPEA, and EDCI 
in DMF at room temperature yielded the desired products 
(16a-16c).  
 
Scheme 3.6. Synthesis of analogues with 
a 1-phenethyl core. Reagents and 
conditions: a) 3,4-dichlorophenylacetic 
acid, HOBt, DIPEA, EDCI, RT. 
Scheme 3.4. Synthesis of analogue with aromatic core. 
Reagents and conditions: a) 3,4-dichlorophenylacetic acid, 
HOBt, DIPEA, EDCI, RT; b) NaH, MeI, RT. 
Scheme 3.5. Synthesis of 
U50,488 analogue with ethylene 
core. Reagents and conditions: a) 
3,4-dichlorophenylacetic acid, 
HOBt, DIPEA, EDCI, RT. 
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In Vitro Evaluation of the KOR Activity of Analogues 
KOR activity was determined 
via a DiscoveRx HitHunter® cAMP 
Assay, as depicted in Figure 3.6. 
This in vitro measure of receptor 
activation utilizes CHO cells 
overexpressing the KOR. Forskolin 
is used to induce the production of 
cAMP. Activation of the receptor via  
KOR agonists results in the release of Gαі which inhibits the production of cAMP. The levels 
of cAMP can then be quantified via luminescence using a plate reader.2 The resulting dose-
response data was then normalized to vehicle and forskolin only control values and analyzed 
using nonlinear regression with GraphPad Prism v6.07. 
 
Compound # 
EC50 ± SEM 
nM 
Compound # 
EC50 ± SEM 
nM 
Compound # 
EC50 ± SEM 
nM 
(-)-U50,488 0.12 ± 0.02 9f 0.62 ± 0.05 9u 0.46 ± 0.21 
4a 24 ± 6.0 9g 2.8 ± 0.5 9v 1.9 ± 0.7 
4b 4.0 ± 1.0 9h 1.1 ± 0.3 9w 1.5 ± 0.7 
4c > 10,000 9i 1.8 ± 0.8 9x 0.16 ± 0.03 
4d > 10,000 9j 1.6 ± 0.1 9y 0.35 ± 0.09 
4e 39 ± 2.0 9k 3.0 ± 0.7 9aa > 10,000 
4f 0.75 ± 0.04 9l 5.0 ± 1.0 9ab > 10,000 
4g 210 ± 60 9m 7.0 ± 2.0 9ac 1.2 ± 0.6 
7a 24 ± 1 9n 8.0 ± 3.0 9ad > 10,000 
7b > 10,000 9o 8.0 ± 2.0 9ae > 10,000 
9a 30 ± 10 9p 16 ± 4 12 > 10,000 
9b 3.3 ± 0.2 9q 100 ± 20 14 > 10,000 
9c 4.0 ± 1.0 9r > 10,000 16a 0.007 ± 0.002 
9d 7.0 ± 1.0 9s 0.32 ± 0.08 16b 0.14 ± 0.02 
9e 4.2 ± 1.0 9t 20 ± 7 16c 0.005 ± 0.001 
Figure 3.6. Depiction of the GPCR signaling pathway of the 
DiscoveRx cAMP functional assay. 
Table 3.1. KOR activity of analogues in which one region of U50,488 is modified. 
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The KOR activity for each of the analogues in which the pyrrolidine group is modified 
is shown in Table 3.1. Replacement of the pyrrolidine with 6-membered analogues 
(piperidine (4a), morpholine (4c), N-methyl piperazine (4d)) results in decreased potency, 
compared to (-)-U50,488. Specifically, the incorporation of a second heteroatom (morpholine 
(4c), N-methyl piperazine (4d)) results in complete loss of KOR activity. Based on these 
trends, we hypothesize that the binding pocket for the pyrrolidine group is a small and unable 
to accommodate larger cyclic groups. In addition, it appears that this pocket does not have an 
H-bond donor in close enough proximity to bind with the morpholine. Interestingly, 
replacement of the pyrrolidine with azepane (4b), however, is better tolerated. We rationalize 
this observation based on the azepane ring remaining in a puckered conformation. This 
conformation more closely resembles the conformation of pyrrolidine than the possible 
conformations of the cyclohexane ring (boat or chair conformations). In regards to non-
cyclized compounds, the data supports our hypothesis above that the binding pocket is small. 
Consequently, the small, alkyl amines we designed (diethylamine (4e) and 
methylpropylamine (4f)) are much better tolerated than the bulky amine, N-ethyl-2-
phenylethanamine (4g).  
Next, the resulting KOR activity for analogues of the N-alkyl group will be examined. 
According to the data, homologation from a methyl to an ethyl group (7a) decreases the 
potency, compared to (-)-U50,488 by 200-fold, indicating that there is likely an unfavorable 
steric clash in the binding site.  Further validation of this hypothesis is provided by 
substitution with a benzyl group (7b), which eliminates KOR activity.  
In regards to the KOR activity of the aryl group, an unsubstituted phenyl (9a) results 
in decreased potency, as expected based on previous SAR trends.3-4 Further confirming 
previous studies, it is evident that electron withdrawing groups (EWGs), such as Br, Cl, F, 
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CF3, and NO2 (9b-9f, 9h-9k), are preferred in both the meta and para positions of the aryl 
ring. Correspondingly, the compounds with aliphatic groups, such as CH3 and CH(CH3)2 (9l-
9o), or electron donating groups (EDGs), such as OCH3 (9p-9q), are less potent than the 
corresponding substitutions with EWGs.6-8 Specifically, one analogue (9g) incorporating 
both an EWG (Br) and an EDG (OCH3) has activity more closely matching the molecule with 
only the corresponding EWG [compare 9g (3-Br,4-OCH3), 9f (3-Br), and 9q (4-OCH3)]. This 
observation demonstrates that the presence of a single EWG can overcome a large portion of 
the KOR activity loss caused by an EDG. In addition, we analyzed the effect of KOR activity 
on analogues with a single substituent. In regards to the EWG and neutral analogues, there is 
not a clear trend for preference of the meta or para position. However, upon examination of 
the EDGs, the meta substituted OCH3 group is greater than 6-fold more potent than the 
corresponding para substituent. Next, in regards to the steric effects of bulky substitutions, a 
4-phenyl substitution results in a complete loss of KOR activity (9r). Conversely, a 2-napthyl 
substituent (9s) leads to potent KOR activity; whereas a 3-napthyl substituent (9t) leads to 
activity closely matching that of an unsubstituted phenyl group. This result could indicate 
that there is an additional hydrophobic binding pocket that the 2,3-napthyl substituted 
analogue can access, which results in greater KOR activity. Finally, in regards to various 
substitution patterns for the halogens, we originally hypothesized that replacement of the 
chloro- groups with fluoro- groups would not significantly change KOR activity. In addition, 
we hypothesized that the 2,4-dichloro- analogue would have greater activity than the 2,6-
dichloro- analogue. We observed that the 2,4-dichloro- analogue (9v) and the 3,4-difluoro- 
analogue (9w) are slightly more potent than the corresponding substitutions in only one 
position. We also observed similar potencies for the 2,6-dichloro- substitution pattern (9u), 
the 3-Cl,4-F analogue (9x), and the 3-F,4-Cl analogue (9y). Specifically, the                      
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potency of the 2,6-dichloro substituent (9u) was greater than we hypothesized. We propose 
this could be caused by the ortho substituents locking the molecule into a favorable 
conformation.  
In regards to analogues with a modified linker region, the KOR activity shows that 
extension of the linker by one or two methylene units is not tolerated (9aa-9ab). This result 
can be rationalized by a shallow binding pocket for the aryl group, which is further validated 
by 9r, as described above. The addition of an oxygen atom, however, is tolerated (9ac). We 
hypothesize that this could be the result of an additional H-bonding interaction. Next, the data 
shows that conformational constraint of U50,488 analogues via a cyclopropyl or cyclopentyl 
group leads to a complete loss of KOR activity (9ad-9ae), signifying that some degree of 
flexibility of the molecules is preferred. 
Finally, the KOR activity for analogues with changes to the cyclohexane ring was 
determined. The data shows that replacement with an aromatic ring leads to complete loss of 
KOR activity (12), likely due to the altered basicity of the amine. In addition, cleavage of the 
backbone to an ethylene linker results in a loss of KOR activity (14). As expected, based on 
literature precendence,9 the racemic 1-phenethyl derivative resulted in a nearly 20-fold 
increase in potency (16a), compared to (-)-U50,488. Subsequent synthesis of the enantiopure 
analogues, (16b-16c) and determination of their KOR activity, shows that the (S) derivative 
(16c) is the eutomer, with the highest potency of any of analogue tested. 
 
Specific Aim #2: Evaluate ex vivo efficacy, including inhibition of cAMP accumulation 
and stimulation of ERK. Select analogues, as depicted in Figure 3.7, were further evaluated 
for ex vivo efficacy. These analogues were prioritized for ex vivo testing because their KOR 
activity was inconsistent with the SAR trends we observed. For example, substitution of the 
pyrrolidine ring with six-membered analogues resulted in decreased potency compared to      
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(-)-U50,488. However, substitution with an azepane ring was tolerated (4b). Also, regarding 
changes in the substitution pattern, a 2,6-dichloro substituted aryl group resulted in  
approximately a 3-fold 
decrease in potency (9u), 
compared to                         
(-)-U50,488; whereas, a 
2,4-dichloro substituted 
aryl group decreased 
potency by nearly 16-fold. 
Lastly, additional alkyl spacers and conformational constraint of U50,488 resulted in a loss 
of KOR activity. However, the addition of an oxygen spacer was tolerated (9ac). Our 
hypothesis is that ligands with activity inconsistent with our SAR trends may be promoting 
a unique receptor conformation with the ability to differentially regulate signaling pathways. 
Specifically, these analogues were tested for their ability to activate Gαi and ERK signaling 
in primary cultures of adult rat peripheral sensory neurons. Gαi and ERK activation are indices 
for antinociception and nociception, 
respectively. 
  In regards to the ability to inhibit AC 
activity, the analogues have similar activity 
compared to (-)-U50,488 (Figure 3.8). It is 
known that this pathway is responsible for 
leading to antinociceptive effects. Therefore, based on this data, we anticipate that 
compounds 4b, 9u, and 9ac will have similar analgesic effects as compared to (-)-U50,488. 
   
4b 9u 9ac 
Figure 3.8. Inhibition of cAMP accumulation 
for KOR analogues. 






Unlike (-)-U50,488, however, the 
analogues tested do not activate ERK (Figure 
3.9). Since activation of ERK ultimately leads 
to dysphoric effects, we expect that these 
ligands will cause decreased incidence of 
dysphoria. These results indicate that all three 
of the compounds have signaling profiles that 
differ from that of (-)-U50,488.  
Thus, the three analogues described above all have maintained efficacy for pathways 
leading to nociception (cAMP accumulation assay), and reduced efficacy for signaling 
pathways leading to nociception (ERK phosphorylation assay). Therefore, each of the ligands 
will proceed for evaluation of their ability to inhibit CGRP release. 
 
Specific Aim #3: Evaluate ex vivo inhibition of CGRP release. Based on the success of the 
ligands, as described above, 4b, 9u, and 9ac were assessed for their ability to inhibit 
calcitonin gene-related peptide release (CGRP). CGRP is a neuropeptide released by the 
nerve endings of activated nociceptors and its neurosecretion can be used as an index of the 
overall, integrated activity of nociceptor ability. As such, this assay provides a translational 
measure for antinociception, i.e. the action of drugs to alter CGRP has high fidelity with the 
effects in the behavioral assay.  
In regards to the concentration-
response curve (CRC) (Figure 3.10), the 
ligands tested produce monotonic CRCs, as 
opposed to the inverted-U CRC displayed 
by (-)-U50,488. However, in contrast to the 
Figure 3.9. ERK phosphorylation of select KOR 
ligands. 











inhibition of cAMP accumulation, the potency of the ligands differs, as follows: 9u > 9ac > 
4b.  The difference in the CGRP release amongst the three ligands is important because it 
indicates that they may be differentially regulating alternative pathways leading to 
nociception i.e. these ligands may be activating different MAPKs. 
 Synthesis and In Vitro Analysis of Enantiopure Analogues 
 Based on the success of the functionally selective KOR ligands described above, 
synthesis of enantiopure ligands was initiated in order to determine the eutomer for each of 
the trans-isomers of the functionally selective ligands (Figure 3.11). Structurally, these 
ligands differ in three regions of the molecule: the pyrrolidine group, linker region, and aryl 
group. Thus, it was envisioned that ligands incorporating more than one of the modifications 
above would result in additive changes to KOR activity. Therefore, in order to determine if 
additive changes result in additive KOR activity, we also initiated synthesis of enantiopure 
























Figure 3.11. Proposed enantiopure analogues. 
60  
The chemistry related to these analogues begins as described previously with (8) 
(Scheme 3.6).10 The racemic diamine 8 and 2,3-di-p-toluoyl-D-tartaric acid, or 2,3-di-p-
toluoyl-L-tartaric acid, respectively, were dissolved separately in 400 mL methanol at 60oC. 
The solutions were then mixed and allowed to cool to room temperature, and were further 
cooled to 0oC. The solid was then filtered and recrystallized three times from methanol. The 
parent amine was then regenerated by partitioning between dichloromethane (DCM) and 
aqueous (20%) KOH. Fractional crystallization with 2,3-di-p-toluoyl-D-tartaric acid yielded 
the (-)-(S,S) enantiomer; whereas 2,3-di-p-toluoyl-L-tartaric acid yielded the (+)-(R,R) 
enantiomer. Racemic diamine 3b was resolved into its enantiomerically pure form, as 
described above, except methanol was replaced with ethanol as the crystallization solvent. 
The four enantiomeric diamines were then used to prepare the optically active compounds 
outlined below via reaction with the corresponding acid chloride in DCM. 
 
Scheme 3.7. Synthesis of enantiopure analogues. Reagents and conditions: a) (i) 2,3-di-p-toloyl-D-tartartic 
acid or 2,3-di-p-toloyl-L-tartartic acid, respectively (ii) KOH; b) R6CH2COCl, 0oC. 
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 The KOR activity of the compounds, 
determined via a DiscoveRx cAMP functional 
assay, are presented in Table 3.2. It should be 
noted that this data is preliminary (n=2 for all 
compounds except (+)-18, where n=1). Based on 
the activity, however, the activity of the (-)-
enantiomers closely matches the activity observed 
from the racemic mixtures. The (+)-enantiomers, 
however, are less potent than the (-)-enantiomers 
and the racemic mixture, in all cases.  
Next, in regards to the molecules with modifications in two regions, (-)-17 is more 
potent than the corresponding analogue with modification of the pyrrolidine to an azepane   
(-)-4b, but is less potent than the analogue incorporating a 2,6-dichlorophenyl substituent       
(-)-9u. The other analogues, however, all have decreased potency compared to the analogues 
incorporating only one of the modifications, i.e. (+)-17 is less potent than either (+)-4b or 
(+)-9u; (-)-18 is less potent than either (-)-4b or (-)-9ac; (+)-18 is less potent than either      
(+)-4b or (+)-9ac. For the analogues we tested, these results indicate that changes to more 
than one portion of the molecule do not result in additive changes to KOR activity, but rather 
decrease potency compared to analogues incorporating only one modification (with the 





Compound # EC50 ± SEM nM 
(-)-U50,488 0.12 ± 0.02 
(+/-)-9u 0.46 ± 0.21 
(-)-9u 0.36 ± 0.04 
(+)-9u 15 ± 4 
(+/-)-9ac 1.2 ± 0.6 
(-)-9ac 0.9 ± 0.2 
(+)-9ac 11 ± 6 
(+/-)-4b 4.0 ± 1.0 
(-)-4b 4 ± 3 
(+)-4b 9.5 ± 0.7 
(-)-17 0.8 ± 0.2 
(+)-17 18 ± 9 
(-)-18 9 ± 4 
(+)-18 46 ± 0 
Table 3.2. KOR activity of racemic and 
enantiopure analogues. 
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Summary of Results 
Thus, in summary, we have designed several compounds, incorporating modifications 
to five regions of U50,488, including the pyrrolidine group, N-alkyl substituent, the linker 
region, the aryl group, and the cyclohexane ring. Upon successful synthesis of these 
analogues, the KOR activity was evaluated.  
Based on these SARs we observed, we prioritized three molecules, 4b, 9u, and 9ac 
for subsequent ex vivo evaluation of cAMP accumulation and stimulation of ERK. The results 
indicate that each of these molecules have signaling profiles that differ from that of                     
(-)-U50,488. We then evaluated ex vivo inhibition of CGRP release as a translational measure 
for antinociception. The data showed that the ligands produce monotonic CRCs, as opposed 
to the inverted-U CRC produced by (-)-U50,488. However, the potency of the ligands differs: 
9u > 9ac > 4b.  
Finally, the success of these ligands prompted further investigation into the 
stereochemical preference for each of these ligands, as well as the effects of analogues 
incorporating changes to two of the sites listed above. The preliminary data suggests that the 
(-)-enantiomer is the eutomer in all cases. Finally, incorporating two changes to the 
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Thus, by accomplishing the aims outlined herein, we have shown that structural 
modifications to the U50,488 scaffold alters ligand efficacy for specific signaling pathways. 
Specifically, we have identified three functionally selective KOR ligands, 3b, 9u, and 9ac, 
with efficacy similar to that of (-)-U50,488, which do not activate ERK. We anticipate that 
these molecules will be useful in designing better biological probes for studying KOR-
mediated antinociception. 
We have designed several compounds, incorporating modifications to five regions of 
U50,488, including the pyrrolidine group, N-alkyl substituent, the linker region, the aryl 
group, and the cyclohexane ring. Upon successful synthesis of these analogues, the KOR 
activity was evaluated.  
To begin, in regards to modification of the pyrrolidine group, we observed that 6-
membered analogues and non-cyclic bulky amines resulted in decreased potency. Further, 
analogues which incorporate a second heteroatom result in a complete loss of KOR activity. 
On the contrary, replacement with azepane and small, non-cyclic amines are tolerated. Thus, 
we hypothesize that the pyrrolidine group fits into a somewhat small binding pocket that does 
not have H-bond donors in close enough proximity to allow additional interactions with 
incorporation of second heteroatom. In addition, we propose the azepane substituent is better 
tolerated than the 6-memebered analogues because it adopts a puckered conformation that 
much more closely resembles the envelope conformation of a five-membered ring. 
In regards to modification of the N-alkyl substituent, homologation to an ethyl or 
benzyl group results in a decrease of KOR, likely indicating that there is a steric clash in the 
binding site by addition of these aliphatic and aromatic groups. 
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Next, pertaining to the aryl group, we confirmed previous SAR studies showing that 
EWGs are preferred in both the meta and para positions. Accordingly, small aliphatic groups 
and EDGs result in decreased potency compared to the corresponding substitutions with 
EWGs. In addition, there is no clear preference for a substituent to be in the meta vs para 
position, except for with the case of OCH3, which results in a 6-fold decrease in potency 
when in the meta position. Our data has also shown that a 4-Ph substitution results in a loss 
of KOR activity, while a 2,3-napthyl is well tolerated, and a 3,4-napthyl leads to KOR similar 
to that of an unsubstituted phenyl group. Our hypothesis is that the hydrophobic binding 
pocket has somewhat of a “bent” shape, making it ideal to accommodate a 2,3-napthyl group 
rather than a 3,4-napthyl group. Along this same model, the hydrophobic pocket would not 
accommodate a 4-Ph substituent, which corresponds to the trends we observed. Next, in 
investigation of various substitution patterns, we observed similar potencies of the 2,6-
dichloro analogue, the 3-Cl,4-F analogue, and the 3-F,4-Cl analogue. In addition, the 2,4-
dichloro analogue and the 3,4-difluoro analogue are slightly more potent that what we have 
observed for the corresponding substitutions in only one position. We were surprised to learn 
that the 2,6-dichloro analogue is well tolerated. We hypothesize that these ortho substituents 
hold the analogue in a much more rigid conformation, in which it preferentially remains in 
the pharmacologically active form.  
In addition, we evaluated the effects of KOR activity when the linker region was 
modified. First, extension of the linker by one or two methylene units resulted in a loss of 
KOR activity, which can be rationalized by a shallow binding pocket. Interestingly, the 
addition of an oxygen atom in the linker region is tolerated. We hypothesize that the oxygen 
atom may be forming a H-bond with the receptor in order to afford this activity. Lastly, 
conformational constraint of U50,488 via a cyclopropyl or cyclopentyl group is not tolerated, 
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indicating that some degree of flexibility is preferred, or that these groups lock U50,488 into 
an unfavorable conformation. 
Lastly, we evaluated KOR activity when the cyclohexane ring was altered. The data 
indicates that replacement with an aromatic group leads to a loss of KOR activity, signifying 
that the basic nitrogen is necessary for activity. Next, cleavage of the backbone to an ethylene 
linker also leads to a loss of KOR activity. Lastly, based on literature precedence, we 
synthesized analogues with a 1-phenethyl backbone (racemic and enantiopure). These 
derivatives resulted in a nearly 20-fold increase in potency, compared to (-)-U50,488. 
Specifically, the (S) enantiomer yields the highest potency of any analogues tested. 
Thus, based on the SARs trends described above, we prioritized three molecules, 4b, 
9u, and 9ac for subsequent ex vivo testing. Specifically, these analogues were prioritized, as 
detailed above, because their KOR activity was inconsistent with the SAR trends we 
observed. These ligands were evaluated in an assay of cAMP accumulation and stimulation 
of ERK. The results show that each of the ligands inhibit AC activity similar to that of                
(-)-U50,488, but, unlike (-)-U50,488, do not activate ERK. Therefore, these results indicate 
that each of these molecules have signaling profiles that differ from that of (-)-U50,488. 
Consequently, since 4b, 9u, and 9ac have maintained efficacy for pathways leading to 
antinociception, and decreased efficacy for pathways leading to nociception, all ligands were 
further evaluated for CGRP release. 
CGRP release was evaluated as a translational measure for antinociception. The data 
from this assay showed that the ligands produce monotonic CRCs, as opposed to the inverted-
U CRC produced by (-)-U50,488. However, the potency of the ligands differs: 9u > 9ac > 
4b. The difference in the CGRP release amongst the three ligands is important because it 
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indicates that they may be differentially regulating alternative pathways leading to 
nociception i.e. these ligands may be activating different MAPKs. 
Finally, the success of these ligands prompted further investigation into the 
stereochemical preference for each of the functionally selective ligands described above, as 
well as the effects of analogues incorporating changes to two of the sites listed above. The 
preliminary data shows that the activity of the (-)-enantiomers closely matches the activity of 
the racemic mixtures. In addition, the (-)-enantiomers have the greatest potency for the KOR, 
but also, the presence of the (+)-enantiomers in the racemic mixtures appears to have little 
effect on the overall KOR activity. In order to rationalize this data, we propose that the (+)-
enantiomers do not activate pathways leading to nociception.  
In regards to the analogues which incorporate modifications in two regions, we 
observed, similarly to the results above, that the (-)-enantiomer is the eutomer in all cases. In 
addition, incorporating two changes to the molecules, as outlined above, results in decreased 
potency in all but one analogue (except (-)-17). Thus, for the molecules tested (except (-)-
17), we can conclude that changes to more than one portion of U50,488 do not result in 
additive changes in KOR activity, but rather decrease the overall KOR activity. 
In the future, the compounds that we have identified as functionally selective KOR 
ligands, 3b, 9u, and 9ac, will be evaluated for off-target affinity for binding to mu and delta 
opioid receptors. Analogues with an affinity of greater than 500 nM for the mu and delta 
receptors will then be tested in vivo in a rat model of thermal allodynia. Specifically, paw 
withdrawal latency will be measured at various doses of the above ligands. In this assay, we 
anticipate monotonic dose response curves for inhibition of PGE2-induced thermal allodynia, 
similar to the results obtained by the ex vivo assay measuring inhibition of CGRP. Thus, we 
anticipate that ligands identified above, which have high efficacy for Gαi signaling, and do 
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not activate ERK will have monotonic DRCs with strong antinociceptive efficacy in the rat 
























V. Experimental Data 
General Experimental Procedures. All reactions were performed in glassware dried in 
an oven at 120°C overnight and cooled under a stream of argon. Solvents were obtained 
from a dry solvent system that dried solvent by passage through two columns of alumna 
and degassed by extensive argon sparging. Flash column chromatography (FCC) was 
performed on silica gel (4-60 μm) from Sorbent Technologies. Reactions and 
chromatography was monitored by thin-layer chromatography (TLC) on 0.25 mm 
Analtech GHLF silica gel plates and visualized by UV light (254 nm) and 
phosphomolybdic TLC stain. 1H and 13C NMR spectra were acquired on a 500 MHz 
Bruker AVIII spectrometer equipped with a cryogenically-cooled carbon observe probe. 
High resolution mass spectroscopy (HRMS) analyses were carried out on a Waters LCT 
Premiere Time of Flight detector with a photodiode array UV detector. Purification was 
carried out via FCC or Mass Directed Fractionation on an Agilent 1200 instrument with a 
photodiode array detector attached to an Agilent 6120 quadrupole mass spectrometer. 
HPLC was conducted using a Waters Acquity BEH C18 equipped with a Waters XBridge 
C18 column (19 × 150 mm, 5µm), at a flow rate of 20 mL/min, over 3.5 minutes. Specific 
rotations were recorded on a Rudolph Autopol III (λ = 589 nm) at 20 ℃ using a polarimeter 
cell with a path length of 1 dm. Compounds tested in biological assays were identified  
as having a purity of ≥ 95% via HPLC. Commercially available reagents were used 
directly without further purification.  
 
General Procedure for Amino-alcohol Formation: Cyclohexene oxide (1 mL, 10 mmol) 
and appropriate amine (12 mmol) in EtOH were refluxed overnight and concentrated. The 
product was formed in quantitative yield and was used without further purification.  
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General Procedure for Diamine Formation: Methanesulfonyl chloride (MsCl) (1 mL, 12 
mmol) was added dropwise to an ice-cold solution of the appropriate amino-alcohol and Et3N 
(4.40 mL, 30 mmol) in anhydrous Et2O (10 mL). The reaction mixture was stirred for 30 
minutes and methylamine (41% aqueous solution, 5 mL) was added. The reaction was then 
allowed to warm to room temperature, with vigorous stirring, overnight. The biphasic mixture 
was separated, and the aqueous layer was further extracted with Et2O (150 mL). The 
combined organics were dried over Na2SO4 and concentrated in vacuo. The crude reaction 
mixture was utilized without purification. As such, the yields are calculated based on the 
amount of crude reaction mixture used. 
 
General Procedure for Amide Formation:  
Method A: Diamine (1 equiv), acid (2 equiv), HOBt (2 equiv), and DMF were added to a 
dry round bottom flask. DIPEA (2 equiv) and EDCI (2 equiv) were then added, and the 
reaction was stirred at room temperature for 4 hours. After completion of the reaction, the 
mixture was concentrated and the resulting gum was partitioned between EtOAc and 
saturated aqueous NaHCO3. The organic layer was then dried over Na2SO4 and concentrated. 
The samples were purified using mass-directed reverse phase HPLC. 
Method B: Acid chloride (1.1 equiv) was added dropwise to an ice-cold solution of diamine 
(1 equiv) in anhydrous DCM. The reaction was allowed to warm to room temperature. After 
2 hours, the reaction was washed with saturated aqueous NaHCO3. The organic layer was 
then dried over Na2SO4, concentrated and purified by mass-directed reverse phase HPLC or 
FCC. 
Method C: Diamine (1 equiv), acid (1 equiv), Et3N (0.4 mL/mol), and PyBrop (1.2 equiv) 
were added to a dry round bottom flask. The flask was purged with argon and the cooled to 
0oC. Anhydrous DCM was then added to the flask, and the mixture was stirred for 1 hour. 
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After 1 hour, the reaction was washed with H2O, dried over Na2SO4, and concentrated. The 
product was purified via mass-directed reverse phase HPLC or FCC. 
Compounds 2a-2e, 2g, 3a-3e, 3g, 4a-4d, 4g, 5, 6a-6b, 7a-7b, 8, 9a-9w, 9aa-9ae, 11, 14, and 
16a-16c were found to be in agreement with previously reported values.1-3 
trans-(+/-)-2-(Methyl(propyl)amino)cyclohexanol (2f). Prepared according 
to the general procedure for aminoalcohol formation to give the title compound in 
quantitative yield. The resulting viscous red oil was used without further purification. 1H 
NMR (500 MHz, Chloroform-d) δ 4.72 (d, J = 2.5 Hz, 1H), 3.96 (d, J = 2.5 Hz, 1H), 3.46 – 
3.31 (m, 1H), 3.10 (s, 5H), 2.84 (dd, J = 6.2, 4.9 Hz, 4H), 2.32 (s, 2H), 2.17 – 2.06 (m, 1H), 
2.06 – 1.97 (m, 1H), 1.89 – 1.77 (m, 2H), 1.44 – 1.31 (m, 1H), 1.31 – 1.10 (m, 5H). 13C NMR 
(126 MHz, CDCl3) δ 88.52, 80.56, 69.55, 53.24, 37.21, 28.72, 27.29, 24.11. HRMS [M+H]: 
172.1696 (calcd), 172.1706 (found). 
trans-(+/-)-N-Methyl-2-(Methyl(propyl)amino)cyclohexanamine (3f). 
Prepared from 2f according to the general procedure for diamine formation to give the title 
compound. The resulting viscous red oil was subsequently used without further purification. 




acetamide ((-)-4b). Prepared according to the general procedure for amide formation 
(method B) from (-)-3b (238 mg, 1.1 mmol) and 3,4-dichlorophenylacetyl chloride (491 mg, 
2.2 mmol) in 98% yield. 1H NMR (500 MHz, Chloroform-d) δ 7.41 (s, 1H), 7.37 (d, J = 6.6 
Hz, 1H), 7.23 (d, J = 8.8 Hz, 2H), 4.90 (s, 1H), 4.33 (s, 1H), 3.92 (s, 1H), 3.70 (s, 2H), 3.08 
(d, J = 54.7 Hz, 6H), 2.25 (s, 2H), 1.68 (tt, J = 103.0, 53.2 Hz, 17H). 13C NMR (126 MHz, 
CDCl3) δ 173.14, 135.76, 132.11, 131.81, 130.65, 130.22, 129.66, 67.32, 56.49, 48.52, 40.95, 
30.12, 28.28, 28.17, 24.86, 24.75, 24.55, 23.92. HRMS [M+H]: 397.1808 (calcd), 397.1808 
(found). Melting point: 162℃ (dec). HPLC tR = 1.48 min; purity = 98.1%, using a gradient 
of 85% - 100% acetonitrile/pH 9.8 aqueous ammonium hydroxide as the mobile phase.     
[α]20D (MeOH) = – 31.8o (c = 0.011 g/mL). 
(1R,2R)-(2-(3,4-Dichlorophenyl)-N-methyl-N-(2-(azepan-1yl)cyclohexyl) 
acetamide ((+)-4b). Prepared according to the general procedure for amide formation 
(method B) from (+)-3b (231 mg, 1.1 mmol) and 3,4-dichlorophenylacetyl chloride (491 mg, 
2.2 mmol) in 94% yield. 1H NMR (500 MHz, Chloroform-d) δ 7.44 – 7.32 (m, 2H), 7.23 (d, 
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J = 8.8 Hz, 1H), 4.90 (s, 1H), 4.33 (s, 1H), 3.81 (d, J = 110.9 Hz, 3H), 3.08 (d, J = 55.4 Hz, 
6H), 2.36 (d, J = 108.0 Hz, 3H), 2.05 – 1.26 (m, 13H). 13C NMR (126 MHz, CDCl3) δ 173.14, 
135.76, 132.11, 131.82, 130.65, 130.23, 129.68, 67.36, 56.50, 48.56, 40.98, 30.13, 28.29, 
28.18, 24.88, 24.77, 24.55, 23.95. HRMS [M+H]: 397.1808 (calcd), 397.1810 (found). 
Melting point: 153℃ (dec). HPLC tR = 1.54 min; purity = 98.0%, using a gradient of 75% - 
95% acetonitrile/pH 9.8 aqueous ammonium hydroxide as the mobile phase.                          
[α]20D (MeOH) = + 30.9o (c = 0.015 g/mL). 
trans-(+/-)-2-(3,4-Dichlorophenyl)-N-methyl-N-(2-(diethylamino)cyclo 
hexyl)acetamide (4e). Prepared according to the general procedure for amide formation 
(method A) from 3e (172 mg, 0.55 mmol) and 3,4-dichlorophenylacetic acid (247 mg, 1.0 
mmol) in 42% yield. Melting point: 55‒56℃. 1H NMR (500 MHz, DMSO-d6) δ 7.56 (dd, J 
= 5.5, 8.2 Hz, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.24 (ddd, J = 2.1, 8.3, 13.9 Hz, 1H), 3.85 – 3.56 
(m, 2H), 2.83 (s, 2H), 2.68 (s, 1H), 2.61 – 2.53 (m, 1H), 2.25 (ddq, J = 6.8, 13.4, 40.5 Hz, 
2H), 1.85 – 1.00 (m, 8H), 0.88 (dt, J = 7.1, 16.5 Hz, 6H). 13C NMR (126 MHz, DMSO) δ 
169.42, 137.97, 131.63, 131.00, 130.56, 130.28, 129.25, 60.25, 59.15, 57.64, 53.09, 43.50, 
43.06, 29.89, 27.62, 25.66, 25.46, 25.19, 23.90, 14.96, 14.84. HRMS [M+H]: 371.1652 
(calcd), 371.1642 (found). HPLC tR = 1.37 min; purity = 97.2%, using a gradient of 85% - 
100% acetonitrile/pH 9.8 aqueous ammonium hydroxide as the mobile phase. 
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trans-(+/-)-2-(3,4-Dichlorophenyl)-N-methyl-N-(2-(Methyl(propyl)amino) 
cyclohexyl)acetamide (4f). Prepared according to the general procedure for amide formation 
(method A) from 3f (119 mg, 0.55 mmol) and 3,4-dichlorophenylacetic acid (231 mg, 1.0 
mmol) in 20% yield. 1H NMR (500 MHz, DMSO-d6) δ 7.56 (dd, J = 2.4, 8.2 Hz, 1H), 7.47 
(d, J = 2.1 Hz, 1H), 7.23 (ddd, J = 2.0, 8.3, 13.6 Hz, 1H), 3.90 – 3.46 (m, 2H), 2.79 (s, 2H), 
2.70 – 2.62 (m, 1H), 2.40 – 2.08 (m, 2H), 2.05 (s, 2H), 1.89 – 0.98 (m, 7H), 0.69 (t, J = 7.3 
Hz, 2H). 13C NMR (126 MHz, DMSO) δ 169.49, 137.81, 131.35, 131.09, 130.63, 130.04, 
129.31, 63.90, 63.04, 57.50, 55.18, 53.16, 36.33, 29.76, 27.27, 25.57, 25.27, 21.33, 11.90. 
HRMS [M+H]: 371.1652 (calcd), 371.1616 (found). HPLC tR = 1.46 min; purity = 100.0%, 
using a gradient of 85% - 100% acetonitrile/pH 9.8 aqueous ammonium hydroxide as the 
mobile phase. 
(1S,2S)-(2-(2,6-Dichlorophenyl)-N-methyl-N-(2-(pyrrolidin-1-yl)cyclo 
hexyl)acetamide ((-)-9u). Prepared according to the general procedure for amide formation 
(method B) from (-)-8 (203 mg, 1.1 mmol) and 2,6-dichlorophenylacetyl chloride (491 mg, 
2.2 mmol) in 56% yield. 1H NMR (500 MHz, Chloroform-d) δ 7.31 (d, J = 8.0 Hz, 2H), 7.14 
(dd, J = 8.5, 7.6 Hz, 1H), 4.45 (d, J = 107.7 Hz, 2H), 3.98 (d, J = 16.6 Hz, 1H), 3.90 – 3.39 
76  
(m, 2H), 3.25 (s, 3H), 3.14 – 2.79 (m, 2H), 2.13 (d, J = 45.0 Hz, 3H), 1.85 (dd, J = 39.7, 13.7 
Hz, 5H), 1.56 – 1.14 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 136.12, 132.84, 127.86, 99.97, 
37.19, 29.70, 29.31, 24.54, 23.83. HRMS [M+H]: 369.1495 (calcd), 369.1521 (found). HPLC 
tR = 1.30 min; purity = 97.1%, using a gradient of 85% - 100% acetonitrile/pH 9.8 aqueous 
ammonium hydroxide as the mobile phase. [α]20D (MeOH) = – 10.1o (c = 0.010 g/mL). 
(1R,2R)-(2-(2,6-Dichlorophenyl)-N-methyl-N-(2-(pyrrolidin-1-yl)cyclo 
hexyl)acetamide ((+)-9u). Prepared according to the general procedure for amide formation 
(method B) from (+)-8 (200 mg, 1.1 mmol) and 2,6-dichlorophenylacetyl chloride (494 mg, 
2.2 mmol) in 49% yield. 1H NMR (500 MHz, Chloroform-d) δ 7.31 (d, J = 8.0 Hz, 2H), 7.14 
(dd, J = 8.5, 7.7 Hz, 1H), 4.45 (d, J = 107.6 Hz, 2H), 4.04 – 3.94 (m, 1H), 3.87 (s, 1H), 3.25 
(s, 3H), 3.15 – 2.73 (m, 2H), 2.38 – 2.01 (m, 2H), 1.96 – 1.78 (m, 4H), 1.56 – 1.20 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 136.12, 132.84, 128.54, 127.86, 37.22, 29.30, 24.53, 24.34, 
23.84. HRMS [M+H]: 369.1495 (calcd), 369.1493 (found). HPLC tR = 1.29 min; purity = 
96.7%, using a gradient of 85% - 100% acetonitrile/pH 9.8 aqueous ammonium hydroxide as 
the mobile phase. [α]20D (MeOH) = + 9.9o (c = 0.007 g/mL). 
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trans-(+/-)-(2-(3-chloro-4-fluorophenyl)-N-methyl-N-(2-(pyrrolidin-1-yl) 
cyclohexyl)acetamide (9x). Prepared according to the general procedure for amide formation 
(method A) from 5 (105 mg, 0.55 mmol) and 3-chloro-4-fluorophenylacetic acid (216 mg, 
1.1 mmol) in 18% yield. 1H NMR (500 MHz, DMSO-d6) δ 7.51 – 7.30 (m, 2H), 7.24 (tdd, J 
= 8.5, 4.8, 2.2 Hz, 1H), 3.85 – 3.50 (m, 2H), 2.81 (s, 3H), 2.70 (s, 1H), 2.65 – 2.53 (m, 2H), 
1.91 – 1.37 (m, 8H), 1.37 – 1.03 (m, 2H). 13C NMR (126 MHz, DMSO) δ 169.92, 164.12, 
155.36, 134.60, 131.25, 130.06, 116.80, 58.14, 47.17, 29.59, 25.44, 23.90, 22.90. HRMS 
[M+H]: 353.1791 (calcd), 353.1806 (found). HPLC tR = 1.26 min; purity = 97.0%, using a 
gradient of 85% - 100% acetonitrile/pH 9.8 aqueous ammonium hydroxide as the mobile 
phase. 
trans-(+/-)-(2-(3-fluoro-4-chlorophenyl)-N-methyl-N-(2-(pyrrolidin-1-yl) 
cyclohexyl)acetamide (9y). Prepared according to the general procedure for amide formation 
(method A) from 5 (101 mg, 0.55 mmol) and 3-fluoro-4-chlorophenylacetic acid (213 mg, 
1.1 mmol) in 15% yield. 1H NMR (500 MHz, Chloroform-d) δ 7.49 (td, J = 8.1, 3.3 Hz, 1H), 
7.26 (ddd, J = 28.6, 10.6, 2.0 Hz, 1H), 7.14 – 7.02 (m, 1H), 3.85 – 3.54 (m, 2H), 2.77 (s, 2H), 
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2.59 – 2.29 (m, 7H), 1.85 – 0.97 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 174.18, 163.12, 
161.17, 143.26, 135.38, 131.48, 122.25, 63.92, 62.62, 52.49, 51.59, 34.37, 30.30, 29.89, 
28.78, 28.55, 27.44. HRMS [M+H]: 353.1791 (calcd), 353.1789 (found). HPLC tR = 2.29 
min; purity = 97.7%, using a gradient of 85% - 100% acetonitrile/pH 9.8 aqueous ammonium 
hydroxide as the mobile phase. 
(1S,2S)-2-(3,4-Dichlorophenoxy)-N-methyl-N-((2-(pyrrolidin-1-
yl)cyclohexyl)acetamide ((-)-9ac). Prepared according to the general procedure for amide 
formation (method B) from (-)-8 (215 mg, 1.1 mmol) and 3,4-dichlorophenoxyacetyl chloride 
(520 mg, 2.2 mmol) in 53% yield. 1H NMR (500 MHz, Chloroform-d) δ 7.34 (d, J = 3.0 Hz, 
1H), 7.31 (d, J = 8.9 Hz, 1H), 7.08 (dd, J = 8.9, 2.9 Hz, 1H), 5.37 (d, J = 15.4 Hz, 1H), 4.81 
(d, J = 15.4 Hz, 2H), 3.95 (dq, J = 13.6, 7.0, 6.6 Hz, 1H), 3.55 (ddt, J = 18.1, 11.8, 5.0 Hz, 
1H), 3.22 (d, J = 17.6 Hz, 1H), 3.07 (s, 4H), 2.99 (dt, J = 14.7, 7.5 Hz, 1H), 2.26 (ddq, J = 
35.0, 15.2, 7.6, 6.8 Hz, 2H), 2.13 – 2.01 (m, 1H), 1.89 (ddt, J = 38.0, 33.1, 8.6 Hz, 4H), 1.53 
– 1.22 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 169.67, 157.44, 132.71, 130.52, 124.14, 
117.07, 114.91, 66.96, 60.91, 52.19, 48.07, 29.37, 24.84, 24.44, 24.32, 24.12. HRMS [M+H]: 
385.1444 (calcd), 385.1417 (found). Melting point: 187‒189℃. HPLC tR = 1.40 min; purity 
= 98.8%, using a gradient of 85% - 100% acetonitrile/pH 9.8 aqueous ammonium hydroxide 
as the mobile phase. [α]20D (MeOH) = – 16.6o (c = 0.010 g/mL). 
79  
(1R,2R)-2-(3,4-Dichlorophenoxy)-N-methyl-N-((2-(pyrrolidin-1-
yl)cyclohexyl)acetamide ((+)-9ac). Prepared according to the general procedure for amide 
formation (method B) from (+)-8 (210 mg, 1.1 mmol) and 3,4-dichlorophenoxyacetyl 
chloride (520 mg, 2.2 mmol) in 43% yield. 1H NMR (500 MHz, Chloroform-d) δ 7.34 (d, J 
= 3.4 Hz, 1H), 7.31 (d, J = 8.9 Hz, 1H), 7.08 (d, J = 8.9 Hz, 1H), 5.37 (d, J = 15.5 Hz, 1H), 
4.94 – 4.67 (m, 2H), 3.95 (s, 1H), 3.55 (d, J = 18.2 Hz, 1H), 3.06 (d, J = 8.9 Hz, 4H), 3.00 (s, 
2H), 2.34 – 2.13 (m, 2H), 2.13 – 2.02 (m, 1H), 2.02 – 1.72 (m, 4H), 1.52 – 1.15 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 169.67, 157.44, 132.72, 130.53, 117.06, 114.90, 66.97, 60.89, 
52.18, 48.05, 29.38, 24.83, 24.44, 24.30, 24.11. HRMS [M+H]: 385.1444 (calcd), 385.1420 
(found). Melting point: 174‒175℃. HPLC tR = 1.37 min; purity = 98.7%, using a gradient of 
85% - 100% acetonitrile/pH 9.8 aqueous ammonium hydroxide as the mobile phase.         
[α]20D (MeOH) = + 17.7o (c = 0.009 g/mL). 
2-(3,4-Dichlorophenyl)-N-methyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamide 
(12). Prepared from 15 (208 mg, 0.57 mmol) via the action of NaH (60% weight, 0.72 mmol) 
and MeI (0.04mL, 0.66 mmol) in 20% yield. 1H NMR (500 MHz, Chloroform-d) δ 7.29 (d, 
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J = 8.2 Hz, 1H), 7.25 – 7.21 (m, 1H), 7.09 (d, J = 2.1 Hz, 1H), 6.96 – 6.88 (m, 2H), 6.82 (dd, 
J = 8.3, 1.4 Hz, 1H), 6.76 (td, J = 7.5, 1.4 Hz, 1H), 3.40 (s, 2H), 3.30 – 3.10 (m, 7H), 2.00 – 
1.75 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 170.93, 145.74, 135.52, 131.88, 131.30, 129.90, 
129.78, 129.01, 128.83, 118.26, 115.90, 49.73, 41.00, 39.59, 37.84, 30.96, 25.43. HRMS 
[M+H]: 363.1026 (calcd), 363.1029 (found). HPLC tR = 2.76 min; purity = 97.7%, using a 
gradient of 85% - 100% acetonitrile/pH 9.8 aqueous ammonium hydroxide as the mobile 
phase. 
(1S,2S)-2-(2,6-Dichlorophenyl)-N-methyl-N-((2-(azepan-1-yl)cyclo 
hexyl)acetamide ((-)-17). Prepared according to the general procedure for amide formation 
(method B) from (-)-3b (230 mg, 1.1 mmol) and 2,6-dichlorophenylacetyl chloride (493 mg, 
2.2 mmol) in quantitative yield. 1H NMR (500 MHz, Chloroform-d) δ 7.32 (d, J = 8.0 Hz, 
2H), 7.15 (t, J = 8.0 Hz, 1H), 4.93 (s, 1H), 4.46 (s, 1H), 4.00 (s, 1H), 3.38 – 3.05 (m, 4H), 
2.99 (s, 1H), 2.44 (d, J = 64.6 Hz, 3H), 1.89 (d, J = 50.5 Hz, 7H), 1.66 (s, 2H), 1.60 (s, 8H), 
1.44 (d, J = 32.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 136.26, 132.84, 128.61, 127.89, 
65.87, 37.59, 30.32, 27.44, 24.92, 24.60, 24.31, 15.29. HRMS [M+H]: 397.1808 (calcd), 
397.1801 (found). Melting point: 121℃ (dec). HPLC tR = 1.42 min; purity = 99.9%, using a 
gradient of 85% - 100% acetonitrile/pH 9.8 aqueous ammonium hydroxide as the mobile 
phase. [α]20D (MeOH) = – 16.3o (c = 0.010 g/mL). 
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(1R,2R)-2-(2,6-Dichlorophenyl)-N-methyl-N-((2-(azepan-1-yl)cyclo 
hexyl)acetamide ((+)-17). Prepared according to the general procedure for amide formation 
(method B) from (+)-3b (240 mg, 1.1 mmol) and 2,6-dichlorophenylacetyl chloride (493 mg, 
2.2 mmol) in 98% yield. 1H NMR (500 MHz, Chloroform-d) δ 7.32 (d, J = 8.0 Hz, 2H), 7.15 
(t, J = 8.0 Hz, 1H), 4.94 (s, 1H), 4.46 (s, 1H), 4.00 (s, 1H), 3.38 – 2.85 (m, 5H), 2.44 (d, J = 
65.9 Hz, 3H), 1.89 (d, J = 48.3 Hz, 6H), 1.62 (s, 5H), 1.39 (d, J = 56.9 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 170.98, 136.26, 132.85, 128.61, 127.89, 99.97, 67.35, 65.87, 37.57, 
30.35, 27.45, 24.99, 24.78, 24.60, 24.33, 15.29. HRMS [M+H]: 397.1808 (calcd), 397.1811 
(found). Melting point: 149℃ (dec). HPLC tR = 1.45 min; purity = 98.0%, using a gradient 
of 85% - 100% acetonitrile/pH 9.8 aqueous ammonium hydroxide as the mobile phase.     
[α]20D (MeOH) = + 16.5o (c = 0.009 g/mL). 
(1S,2S)-2-(3,4-Dichlorophenoxy)-N-methyl-N-((2-(azepan-1-yl) 
cyclohexyl)acetamide ((-)-18). Prepared according to the general procedure for amide 
formation (method B) from (-)-3b (231 mg, 1.1 mmol) and 3,4-dichlorophenoxyacetyl 
chloride (522 mg, 2.2 mmol) in 99% yield. 1H NMR (500 MHz, Chloroform-d) δ 7.36 (s, 
1H), 7.33 – 7.28 (m, 1H), 7.11 (d, J = 8.5 Hz, 1H), 5.44 (s, 1H), 4.84 (d, J = 35.5 Hz, 2H), 
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3.83 (d, J = 117.3 Hz, 2H), 3.03 (d, J = 68.7 Hz, 6H), 2.25 (d, J = 40.1 Hz, 2H), 2.07 – 1.71 
(m, 5H), 1.62 (s, 4H), 1.45 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 169.94, 157.53, 132.66, 
130.46, 124.06, 117.33, 115.16, 67.38, 48.18, 29.89, 28.28, 28.17, 24.89, 24.76, 24.65, 24.49, 
23.80. HRMS [M+H]: 413.1757 (calcd), 413.1764 (found). Melting point: 138℃ (dec). 
HPLC tR = 1.51 min; purity = 99.6%, using a gradient of 85% - 100% acetonitrile/pH 9.8 
aqueous ammonium hydroxide as the mobile phase.                                                                             
[α]20D (MeOH) = – 21.3o (c = 0.012 g/mL). 
(1R,2R)-2-(3,4-Dichlorophenoxy)-N-methyl-N-((2-(azepan-1-yl) 
cyclohexyl)acetamide ((+)-18). Prepared according to the general procedure for amide 
formation (method B) from (+)-3b (236 mg, 1.1 mmol) and 3,4-dichlorophenoxyacetyl 
chloride (522 mg, 2.2 mmol) in quantitative yield. 1H NMR (500 MHz, Chloroform-d) δ 7.36 
(s, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 5.44 (s, 1H), 4.84 (d, J = 39.2 Hz, 
2H), 3.83 (d, J = 118.5 Hz, 2H), 3.03 (d, J = 70.4 Hz, 6H), 2.63 – 2.08 (m, 3H), 2.08 – 1.53 
(m, 7H), 1.45 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 169.94, 157.53, 132.66, 130.46, 124.06, 
117.32, 115.16, 67.37, 48.21, 29.91, 28.28, 28.17, 24.94, 24.78, 24.67, 24.49, 23.80. HRMS 
[M+H]: 413.1757 (calcd), 413.1783 (found). Melting point: 152℃ (dec). HPLC tR = 1.51 
min; purity = 99.1%, using a gradient of 85% - 100% acetonitrile/pH 9.8 aqueous ammonium 




Cell Lines and Cell Culture. Cells were cultured as previously described.4 The HitHunter 
Chinese hamster ovary cells (CHO-K1) stably expressing the human κ-opioid receptor 
(OPRK1, catalogue no. 95-0088C2) were purchased from DiscoverX Corp. (Fremont, CA) 
and maintained in F-12 media with 10% fetal bovine serum (Life Technologies, Grand Island, 
NY), 1% penicillin/streptomycin/L-glutamine (Life Technologies), and 800 μg/mL geneticin 
(Mirus Bio, Madison, WI). The media of the PathHunter cells was supplemented with an 
additional 250 μg/mL hygromycin B (Mirus Bio). All cells were grown at 37 °C and 5% CO2 
in a humidified incubator. 
 
Forskolin-Induced cAMP Accumulation. Assays proceeded as previously described.4 On 
day 1, ∼80% confluent KOR-CHO cells were detached from culture plates using 
nonenzymatic cell dissociation buffer (Life Technologies) and counted using a 
hemocytometer. Cells were plated at 10,000 cells/well in 20 μL of Cell Plating Reagent 2 
(DiscoveRx) in 384-well tissue culture plates and incubated at 37°C overnight. On day 2, 
stock solutions of all compounds were generated by dissolution in 100% DMSO (Alfa Aesar, 
Ward Hill, MA) to 10 mM. Stock solutions were used to make 10 serial dilutions in 100% 
DMSO at 100× final compound concentrations, and 100× compound concentrations were 
diluted in assay buffer [Hank’s Buffered Salt Solution (HBSS, Life Technologies) with 10 
mM HEPES (Life Technologies)] containing forskolin (DiscoveRx) to yield 5× compound 
concentrations, 100 μM forskolin, and 5% DMSO in assay buffer. The DiscoveRx HitHunter 
cAMP Assay was used according to manufacturer’s instructions. Briefly, media was removed 
from cells, and cells were washed with 10 μL of assay buffer. Assay buffer containing 
antibody reagent (20 μL/ well) was added to cells. A 5 μL potion of 5× compound/forskolin 
solution were added to cells (final concentrations were 1× compound, 20 μM forskolin, and 
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1% DMSO). Cells were incubated at 37 °C and 5% CO2 for 30 min, followed by incubation 
with detection reagents according to manufacturer’s instructions at room temperature 
protected from light overnight. On day 3, luminescence was quantified using a Synergy 2 
plate reader with Gen5 software (BioTek, Winooski, VT). Data were normalized to vehicle 
and forskolin only control values and analyzed using nonlinear regression with GraphPad 
Prism v6.07. 
 
Primary Sensory Neuron Cultures. Primary cultures of rat trigeminal ganglion neurons 
were prepared as described previously.5-6 Cells were maintained in culture for 6 days before 
experimentation. For all experiments, cells were refed with serum-free Dulbecco’s modified 
Eagle’s medium without nerve growth factor on day 5 and used for experiments on the sixth 
day of culture (i.e., after a 24-hour serum/nerve growth factor free period). 
 
Measurement of Cellular cAMP Accumulation. Opioid agonist-induced inhibition of 
PGE2-stimulated adenylyl cyclase activity was measured as described previously.5-6 In brief, 
TG cultures in 48-well plates were washed twice with HBSS containing 20 mM HEPES, pH 
7.4 (wash buffer). Cells were pre-equilibrated in 250 µl of wash buffer per well for 30 min at 
37°C. Cells were then incubated with KOR agonists (various concentrations) in the presence 
of the phosphodiesterase inhibitor rolipram (100 µM) for 15 min at 37°C. A maximal 
concentration of PGE2 (1 µM) was added, and cells were incubated for a further 15 min. As 
appropriate, BK (10 µM) was added during the pre-equilibration period, 15 min before the 
KOR agonists. Incubations were terminated by aspiration of the wash buffer and addition of 
500 µl of ice-cold absolute ethanol. The ethanol extracts from individual wells were dried 
under a gentle air stream and reconstituted in 100 µl of 50 mM sodium acetate, pH 6.2. The 
cAMP content of each 100-µl sample was determined by radioimmunoassay (RIA). 
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Measurement of ERK1/2 Activation. KOR agonist–mediated activation of ERK in 
peripheral sensory neurons was measured as described previously.5-6 Cells were washed twice 
with HBSS containing 20 mM HEPES, pH 7.4 (wash buffer) and pre-equilibrated in 250 µl 
of wash buffer per well for 30 min at 37°C. Cells were then incubated with a KOR agonist 
(100 nM) in the absence or presence of nor-BNI (3 nM) for 0 to 15 min at 37°C. BK (10 µM) 
or vehicle was added during the pre-equilibration period 15 min before the KOR ligand. 
Incubations were terminated by aspiration of buffer and addition of 50 µl of lysis buffer 
supplied with the SureFire phospho-extracellular signal-regulated kinase (pERK) assay kit 
(PerkinElmer Life and Analytical Sciences). Samples were processed according to the 
manufacturer’s directions. The fluorescence signal from pERK was measured in duplicate 
using a Fluostar microplate reader (BMG Labtech GmbH, Offenburg, Germany) with 
AlphaScreen settings. 
 
Measurement of Calcitonin Gene-Related Peptide Release. Opioid agonist-induced 
inhibition of BK/PGE2-stimulated calcitonin gene-related peptide (CGRP) release from TG 
cultures was measured as described previously.5 Cells were washed twice in release buffer 
(HBSS supplemented with 10.9 mM HEPES, 4.2 mM sodium bicarbonate, 10 mM dextrose, 
and 0.1% bovine serum albumin, pH 7.4) and then pretreated with vehicle (Veh) or BK (10 
µM). Fifteen minutes later, cells were treated with opioid ligands or vehicle (15 min), 
followed by PGE2/BK (1 µM/10 µM) or vehicle for an additional 15 min. Levels of CGRP 
obtained from the supernatant (500 µl) were measured with radioimmunoassay. 
 
Data Analysis. All statistical tests were performed using GraphPad Prism software v6.07 (La 
Jolla, CA, USA). One-way ANOVAs were used to compare data from multiple treatment 
groups. Two-way ANOVAs were used to test for significant effects of two factors. For the 
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dose response experiment, non-linear regression analysis was used to calculate the potency 
(EC50) and the efficacy (Emax), with data normalized to salvinorin A, a full KOR agonist. A 
p value of ≤0.05 was used to define significance. When significant differences were found 
for one- and two-way ANOVAs Bonferroni post-hoc tests were used. All values presented 
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 ID SJ-1-169 File SJ160212WT023 Date 18-Feb-2016 Time 7::1::5  Description MDF087649
Time














Peak Number Time AreaAbs Area %Total Height
1 1.84 37 0.13 1176
2 2.23 20 0.07 1053
3 2.33 15 0.05 673
4 2.40 25 0.09 856
5 2.57 18 0.06 909
6 2.61 23 0.08 1110
7 2.71 27644 99.38 894306
8 2.95 35 0.13 2117
µ  
 over 3.5 minutes
6.99e-1
Range: 6.99e-1
 ID SJ-1-171 File SJ160212WT025 Date 18-Feb-2016 Time 8::0::3  Description MDF087700












Peak Number Time AreaAbs Area %Total Height
1 1.50 21 0.08 1105
2 2.13 14 0.05 701
3 2.35 73 0.28 2893
4 2.38 34 0.13 666
5 2.64 15 0.06 758
6 2.84 25841 99.40 693045
µ  




 ID SJ-3-73 File SJ170301WT001 Date 02-Mar-2017 Time 11:11:52 Description CCT138369












Peak Number Time AreaAbs Area %Total Height
1 1.32 320 0.25 15377
2 1.48 127506 98.07 1651757
3 1.64 810 0.62 22875
4 1.70 322 0.25 10128
5 1.77 150 0.12 7542
6 2.08 182 0.14 7106
7 2.23 133 0.10 3744
8 2.77 182 0.14 7286
9 2.99 404 0.31 18344
µ
 over 3.5 minutes
8.541e-1
Range: 8.541e-1
 ID SJ-3-75 File SJ170301WT002 Date 02-Mar-2017 Time 11:16:15 Description CCT138372
















Peak Number Time AreaAbs Area %Total Height
1 1.03 63 0.20 1206
2 1.33 93 0.29 3285
3 1.54 31161 97.98 757351
4 1.64 93 0.29 3890
5 1.76 32 0.10 783
6 1.93 78 0.25 3558
7 2.13 77 0.24 1127
8 2.76 56 0.18 2313
9 2.86 43 0.14 1659
10 2.99 106 0.33 4307
µ
 over 3.5 minutes
245
 ID SJ-1-173 File SJ160212WT026 Date 18-Feb-2016 Time 8::4::6  Description MDF087532
Time














Peak Number Time AreaAbs Area %Total Height
1 2.08 55670 99.92 2036388
2 2.84 43 0.08 1294 µ
 over 3.5 minutes
1.595
Range: 1.595
 ID SJ-1-175 File SJ160212WT027 Date 18-Feb-2016 Time 8::8::9  Description MDF087537
















Peak Number Time AreaAbs Area %Total Height
1 1.64 53 0.10 1618
2 1.89 1101 2.19 58372
3 1.95 49029 97.51 1582017
4 2.08 99 0.20 4139
µ
















Peak Number Time AreaAbs Area %Total Height
1 1.37 39417 97.21 829485
2 1.52 61 0.15 3335
3 1.88 53 0.13 3074
4 2.69 62 0.15 3574
5 2.72 368 0.91 20468
6 2.76 130 0.32 4723
7 2.82 456 1.13 29005
µ
 over 3.5 minutes
2.262e-1
Range: 2.262e-1
 ID SJ-2-71 File SJ160712WT006b Date 12-Jul-2016 Time 11:43:08 Description MDF088668












Peak Number Time AreaAbs Area %Total Height
1 1.46 2104 100.00 93783
µ × 
 over 3.5 minutes
247
Time








 ID SJ-2-69 File SJ160712WT005 Date 12-Jul-2016 Time 10:59:30 Description MDF088646










Peak Number Time AreaAbs Area %Total Height
1 1.33 76 0.06 5118
2 1.43 112 0.09 7546
3 1.57 116395 97.89 1528598
4 1.77 173 0.15 10070
5 2.72 319 0.27 18754
6 2.82 1619 1.36 95400
7 2.86 130 0.11 5267
8 3.00 76 0.06 2773
µ
 over 3.5 minutes
7.151e-1
Range: 7.151e-1
 ID SJ-1-203-160308 File SJ160308WT003 Date 09-Mar-2016 Time 9::9::3  Description SMDF103748












Peak Number Time AreaAbs Area %Total Height
1 1.67 46 0.28 2699
2 1.87 40 0.25 2088
3 2.46 227 1.40 6541
4 2.57 103 0.63 5086
5 2.63 215 1.32 12691
6 2.66 15657 96.12 705626
µ  
 over 3.5 minutes
248
 ID SJ-1-207-160308 File SJ160308WT004 Date 09-Mar-2016 Time 9::3::7  Description SMDF103747
Time














Peak Number Time AreaAbs Area %Total Height
1 2.52 800 3.57 25542
2 2.74 301 1.34 10703
3 2.86 21328 95.09 870646 µ
 over 3.5 minutes
6.957e-1
Range: 6.957e-1
 ID SJ-1-135-160215 File SJ160215WT003 Date 16-Feb-2016 Time 11:56:58 Description SMDF103702












Peak Number Time AreaAbs Area %Total Height
1 1.83 174 1.31 8289
2 1.95 8 0.06 581
3 2.06 13019 98.11 690925
5 2.44 68 0.51 3588
µ
 over 3.5 minutes
249
 ID SJ-1-145 File SJ160212WT001 Date 18-Feb-2016 Time 6::4::6  Description SMDF103689
Time














Peak Number Time AreaAbs Area %Total Height
1 1.23 188 0.52 8944
2 1.25 89 0.25 6351
3 1.53 365 1.01 14119
4 2.01 428 1.19 13292
5 2.03 429 1.19 15327
6 2.25 99 0.27 10409
7 2.28 34460 95.57 1542527
µ  
 over 3.5 minutes
9.949e-1
Range: 9.949e-1
 ID SJ-1-137 File SJ160213WT003b Date 12-Feb-2016 Time 3::0::4  Description MDF031838












Peak Number Time AreaAbs Area %Total Height
1 2.01 179 0.84 7238
2 2.12 21 0.10 968
3 2.27 21125 98.81 990293
4 2.49 54 0.25 2708
µ
 over 3.5 minutes
250
 ID SJ-1-153 File SJ160212WT009 Date 18-Feb-2016 Time 6::0::6  Description SMDF103718
Time














Peak Number Time AreaAbs Area %Total Height
1 1.88 140 0.78 4560
2 1.92 30 0.17 1246
3 1.99 56 0.31 3531
4 2.05 14 0.08 891
5 2.09 47 0.26 4426
6 2.12 17759 98.40 769063
µ
 over 3.5 minutes
1.428e-1
Range: 1.428e-1
 ID SJ-1-139 File SJ160213WT004c Date 12-Feb-2016 Time 3::6::1  Description MDF031813











Peak Number Time AreaAbs Area %Total Height
1 1.34 1 0.05 263
2 1.87 51 1.75 1929
3 2.10 2891 98.20 141777 µ
 over 3.5 minutes
251
 ID SJ-1-191 File SJ160307WT012 Date 07-Mar-2016 Time 12:54:20 Description MDF087792
Time














Peak Number Time AreaAbs Area %Total Height
1 2.29 294 1.29 16371
2 2.32 22603 98.71 899697 µ
 over 3.5 minutes
1.802e-1
Range: 1.801e-1
 ID SJ-1-193 File SJ160307WT014 Date 07-Mar-2016 Time 1::3::3  Description MDF087800












Peak Number Time AreaAbs Area %Total Height
1 2.21 4237 100.00 177558
µ
 over 3.5 minutes
252
ID SJ-1-185 File SJ160307WT006 Date 07-Mar-2016 Time 12:28:05 Description MDF087726
Time














Peak Number Time AreaAbs Area %Total Height
2 2.29 263 1.30 19682
3 2.33 20038 98.70 738645
µ
 over 3.5 minutes
3.236e-1
Range: 3.236e-1
 ID SJ-1-187 File SJ160307WT008 Date 07-Mar-2016 Time 12:36:54 Description MDF087723












Peak Number Time AreaAbs Area %Total




 over 3.5 minutes
253
ID SJ-2-23 File SJ160609WT003 Date 09-Jun-2016 Time 14:08:59 Description MDF088258
Time


















Peak Number Time AreaAbs Area %Total Height
1 0.62 1226 1.91 51692
2 1.13 256 0.40 18029
3 1.90 713 1.11 21183
4 2.00 61935 96.39 2046142
5 2.08 126 0.20 7656
µ
 over 3.5 minutes
2.07
Range: 2.07
 ID SJ-2-25 File SJ160609WT004 Date 09-Jun-2016 Time 14:13:34 Description MDF088373












Peak Number Time AreaAbs Area %Total Height
1 1.71 71 0.11 4183
2 2.00 64475 99.08 2058476
3 2.09 180 0.28 11430
4 2.11 346 0.53 14739
µ
 over 3.5 minutes
254
ID SJ-1-155 File SJ160212WT011 Date 18-Feb-2016 Time 6::8::4  Description MDF087598
Time














Peak Number Time AreaAbs Area %Total Height
1 1.38 20 0.08 984
2 1.46 146 0.57 5650
3 1.96 215 0.84 7517
4 2.00 71 0.28 2366
5 2.13 46 0.18 1746
6 2.18 54 0.21 2108
7 2.24 24957 97.62 1091294
9 2.46 55 0.22 2922
µ




 ID SJ-1-157 File SJ160212WT013 Date 18-Feb-2016 Time 7::7::2  Description MDF087576











Peak Number Time AreaAbs Area %Total Height
1 1.42 13 0.06 789
2 1.46 41 0.18 1824
3 1.97 206 0.92 6682
4 2.01 24 0.11 1383
5 2.12 17 0.08 941
6 2.16 25 0.11 1172
7 2.23 22148 98.43 1007027
8 2.47 28 0.12 1326
µ
 over 3.5 minutes
255
 ID SJ-1-181 File SJ160307WT002 Date 07-Mar-2016 Time 12:10:26 Description MDF087724
Time














Peak Number Time AreaAbs Area %Total Height
1 1.98 78 1.11 3420
2 2.24 6966 98.89 339787 µ
 over 3.5 minutes
9.362e-1
Range: 9.362e-1
 ID SJ-1-183 File SJ160307WT004 Date 07-Mar-2016 Time 12:19:14 Description MDF087737












Peak Number Time AreaAbs Area %Total Height
1 2.22 184 0.85 6185
2 2.47 23 0.11 1356
3 2.54 21325 99.04 926435 µ
 over 3.5 minutes
256
 ID SJ-1-141 File SJ160213WT005b Date 12-Feb-2016 Time 3::9::6  Description MDF031824
Time














Peak Number Time AreaAbs Area %Total Height
1 1.84 138 0.82 5600
2 1.93 85 0.50 4782
3 2.06 16615 98.37 819777
5 2.27 41 0.24 2126
6 2.32 11 0.06 883
µ
 over 3.5 minutes
7.426e-1
Range: 7.426e-1
 ID SJ-1-143 File SJ160213WT006b Date 12-Feb-2016 Time 3::4::1  Description SMDF103630












Peak Number Time AreaAbs Area %Total Height
1 0.91 11 0.07 698
2 1.82 113 0.73 4707
3 1.90 151 0.98 8791
4 2.04 15094 97.85 739813
5 2.26 56 0.36 2931
µ
 over 3.5 minutes
257
Time








ID SJ-1-189 File SJ160307WT010 Date 07-Mar-2016 Time 12:45:37 Description MDF087735






Peak Number Time AreaAbs Area %Total Height
1 2.21 259 2.98 6652
2 2.51 8433 97.02 321950 µ
 over 3.5 minutes
1.649
Range: 1.649
 ID SJ-1-159 File SJ160212WT015 Date 18-Feb-2016 Time 7::6::4  Description MDF087574












Peak Number Time AreaAbs Area %Total Height
1 1.55 30 0.08 1284
2 1.61 58 0.15 2514
3 2.08 470 1.20 15372
4 2.12 53 0.14 2907
5 2.23 46 0.12 1435
6 2.28 65 0.17 4023
7 2.36 218 0.56 14321
8 2.39 38167 97.16 1640113
9 2.54 176 0.45 10073
µ
 over 3.5 minutes
258
 ID SJ-1-161 File SJ160212WT017 Date 18-Feb-2016 Time 7::5::1  Description MDF087583
Time














Peak Number Time AreaAbs Area %Total Height
1 1.62 295 0.43 12638
2 2.08 948 1.38 26494
3 2.27 96 0.14 4231
4 2.35 67157 97.73 2189060
5 2.55 72 0.10 3835
6 2.58 146 0.21 7281
µ
 over 3.5 minutes
9.683e-1
Range: 9.683e-1
 ID SJ-1-147 File SJ160212WT004 Date 18-Feb-2016 Time 6::8::2  Description SMDF103697
















Peak Number Time AreaAbs Area %Total Height
1 2.17 211 0.93 7271
2 2.48 21615 94.82 962148
4 2.65 970 4.26 50406 µ
 over 3.5 minutes
259
Time








ID SJ-2-293 File SJ170202WT004b Date 06-Feb-2017 Time 12:02:21 Description CCT138036 






Peak Number Time AreaAbs Area %Total Height
1 1.30 8715 97.06 250256
3 1.48 196 2.18 8533
4 1.70 68 0.76 3716 µ
 over 3.5 minutes
5.316e-1
Range: 5.315e-1
ID SJ-2-295 File SJ170202WT005b Date 06-Feb-2017 Time 12:16:35 Description CCT138023 















Peak Number Time AreaAbs Area %Total Height
1 1.29 14699 96.71 377557
2 1.58 54 0.35 2931
3 1.70 445 2.93 21153 µ
 over 3.5 minutes
260
 ID SJ-1-149 File SJ160212WT006 Date 18-Feb-2016 Time 6::7::5  Description SMDF103723
Time














Peak Number Time AreaAbs Area %Total Height
1 1.26 18 0.08 907
2 1.70 199 0.87 7928
3 2.21 267 1.17 7699
4 2.52 22393 97.75 996923
5 2.68 31 0.14 1689
µ
 over 3.5 minutes
8.869e-1
Range: 8.869e-1
 ID SJ-1-151 File SJ160212WT007 Date 18-Feb-2016 Time 6::1::9  Description SMDF103716












Peak Number Time AreaAbs Area %Total Height
1 1.46 23 0.12 1067
2 1.92 129 0.64 4529
3 1.96 11 0.06 701
4 2.05 274 1.35 16637
5 2.09 101 0.50 5416
6 2.16 19701 97.01 881318
7 2.52 69 0.34 2521
µ
 over 3.5 minutes
261




















Peak Number Time AreaAbs Area %Total Height
1 0.80 881 2.87 58313
2 1.01 49 0.16 3270
3 1.26 29817 96.97 702662 µ




 ID SJ-1-281 File SJ160512WT002 Date 12-May-2016 Time 4::3::0  Description MDF088066















Peak Number Time AreaAbs Area %Total Height
1 0.72 278 0.99 18274
2 1.79 70 0.25 3709
3 2.07 68 0.24 3700
4 2.29 27592 97.70 1094099
5 2.37 139 0.49 6623
6 2.51 94 0.33 5167
µ
 over 3.5 minutes
262
 ID SJ-1-165 File SJ160212WT021 Date 18-Feb-2016 Time 7::2::3  Description MDF087634
Time














Peak Number Time AreaAbs Area %Total Height
1 1.68 34 0.22 1833
2 2.15 234 1.49 6669
3 2.33 19 0.12 1273
4 2.38 15332 97.74 719418
5 2.61 34 0.22 1811
6 2.96 35 0.22 1887
µ
 over 3.5 minutes
1.352e-1
Range: 1.352e-1
 ID SJ-1-197 File SJ160307WT017 Date 07-Mar-2016 Time 1::6::4  Description MDF087809











Peak Number Time AreaAbs Area %Total Height
1 2.34 3604 100.00 132291
µ
 over 3.5 minutes
263
 ID SJ-1-163 File SJ160212WT019 Date 18-Feb-2016 Time 7::3::5  Description MDF087629
Time













Peak Number Time AreaAbs Area %Total Height
1 1.74 38 0.14 1803
2 2.15 254 0.92 11788
3 2.37 27368 98.68 1369425
4 2.58 73 0.26 4049
µ
 over 3.5 minutes
6.913e-1
Range: 6.913e-1
 ID SJ-3-29 File SJ170210WT001 Date 10-Feb-2017 Time 13:59:42 Description CCT137836












Peak Number Time AreaAbs Area %Total Height
1 1.34 57 0.18 2800
2 1.40 30372 98.81 545028
3 1.55 308 1.00 19056 µ
 over 3.5 minutes
264
 ID SJ-3-31 File SJ170210WT002 Date 10-Feb-2017 Time 14:04:06 Description CCT137883
Time














Peak Number Time AreaAbs Area %Total Height
1 1.37 44800 98.74 726896
2 1.55 334 0.74 20097
3 1.59 67 0.15 4068
4 1.76 116 0.26 6222
5 2.14 55 0.12 2514
µ
 over 3.5 minutes
3.655e-1
Range: 3.655e-1
 ID SJ-1-199 File SJ160307WT019 Date 07-Mar-2016 Time 1::4::5  Description MDF087806












Peak Number Time AreaAbs Area %Total Height
1 2.05 161 1.37 4373
2 2.26 11577 98.63 362114 µ
 over 3.5 minutes
265
 ID SJ-1-201-160308 File SJ160308WT002b Date 09-Mar-2016 Time 10:14:30 Description SMDF103745
Time














Peak Number Time AreaAbs Area %Total Height
1 2.28 29 0.18 1631
2 2.37 310 1.95 9754
3 2.85 15480 97.59 647389
4 2.92 44 0.28 2857
µ
 over 3.5 minutes
9.547e-1
Range: 9.547e-1
 ID SJ-2-165 File SJ161021WT006 Date 21-Oct-2016 Time 16:43:51 Description MDF080079













Peak Number Time AreaAbs Area %Total Height
1 0.81 32 0.14 1859
2 0.86 106 0.47 6141
3 1.23 63 0.28 5193
4 1.25 286 1.27 20810
5 1.99 32 0.14 711
6 2.76 22057 97.70 912242
µ
 over 3.5 minutes
266
 ID SJ-2-75 File SJ160712WT008 Date 12-Jul-2016 Time 11:12:35 Description MDF088688
Time














Peak Number Time AreaAbs Area %Total Height
1 1.11 42135 98.78 937121
3 1.76 216 0.51 14457
4 2.29 67 0.16 3837
5 2.71 131 0.31 6371
6 2.82 105 0.25 6333
µ
 over 3.5 minutes
5.742e-1
Range: 5.742e-1
 ID SJ-2-63 File SJ161003WT009 Date 04-Oct-2016 Time 12:21:12 Description CCT133723











Peak Number Time AreaAbs Area %Total Height
1 1.48 19520 100.00 466061 × 
µ
 over 3.5 minutes
267
 ID SJ-2-159 File SJ161011WT012 Date 19-Oct-2016 Time 16:43:06 Description CCT133712
Time













Peak Number Time AreaAbs Area %Total Height Mass Found
1 9.70 301242 100.00 785412 390.13
µ
 over 3.5 minutes
5.942e-1
Range: 5.883e-1
 ID SJ-2-161 File SJ161011WT013 Date 19-Oct-2016 Time 16:58:49 Description CCT137650














Peak Number Time AreaAbs Area %Total
8.0000
Height Mass Found
1 6.12 956 0.49 4336 390.13
2 8.94 185006 95.66 549593 390.13
3 9.91 7428 3.84 29050 390.13
µ
 over 3.5 minutes
268
 ID SJ-3-77 File SJ170301WT003 Date 02-Mar-2017 Time 11:20:40 Description CCT138371
Time














Peak Number Time AreaAbs Area %Total Height
1 1.42 45877 99.86 980195
2 1.94 66 0.14 3535 µ
 over 3.5 minutes
7.209e-1
Range: 7.209e-1
 ID SJ-3-79 File SJ170301WT004 Date 02-Mar-2017 Time 11:25:00 Description CCT138370
















Peak Number Time AreaAbs Area %Total Height
1 0.72 33 0.14 2259
2 1.22 38 0.17 2887
3 1.41 265 1.17 14932
4 1.45 22234 98.02 616609
5 1.94 59 0.26 2946
6 2.03 55 0.24 2425
µ
 over 3.5 minutes
269
 ID SJ-3-81 File SJ170301WT005 Date 02-Mar-2017 Time 11:29:19 Description CCT138365
Time














Peak Number Time AreaAbs Area %Total Height
1 1.15 84 0.16 4775
2 1.46 79 0.15 4501
3 1.51 52047 99.57 1049779
4 1.93 61 0.12 2933
µ




 ID SJ-3-83 File SJ170301WT006 Date 02-Mar-2017 Time 11:33:35 Description CCT138553















Peak Number Time AreaAbs Area %Total Height
1 1.15 76 0.17 4807
2 1.33 91 0.21 5566
3 1.45 56 0.13 3081
4 1.51 43855 99.12 953568
5 1.70 59 0.13 2408
6 2.09 60 0.14 3407
7 2.11 47 0.11 3027
µ
 over 3.5 minutes
270
